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Abstract
Fibroblast activation is a crucial step in tumor growth and metastatic progression; activated fibroblasts
remodel extracellular matrix (ECM) in primary tumor and metastatic microenvironments, exerting both
pro- and anti-tumorigenic effects. However, the intrinsic mechanisms that regulate the activation of
fibroblasts are not well defined. The signaling axis comprising the calcium-activated Ser/Thr phosphatase
calcineurin (CN), and its downstream target nuclear factor of activated T cells (NFAT), has been shown to
play important roles in in endothelial and immune cell activation, but its role in fibroblasts is not known.
We have shown that deletion of CN in fibroblasts in vitro results in alterations in fibroblast morphology
and function consistent with an activated phenotype relative to wild-type fibroblasts. CN-null fibroblasts
have greater migratory capacity, demonstrate increased collagen secretion and remodeling, and promote
more robust endothelial cell activation in vitro. ECM generated by CN-null fibroblasts contain more
collagen with greater alignment of fibrillar collagen compared to wild-type fibroblast-derived matrix.
These differences in matrix composition and organization impose distinct changes in morphology and
cytoskeletal architecture of both fibroblasts and tumor cells that may represent changes in their
biological function, e.g. activation or epithelial-mesenchymal transition. However, while they are more
activated at baseline, Cn-/- fibroblasts cannot functionally respond to TGF-beta stimulation in multiple
activation assays. They are also unable to upregulate FAP on soft, fibronectin-coated substrates to the
same extent as WT fibroblasts. Consistent with this in vitro phenotype, we show that mice with stromal
CN deletion exhibit a greater incidence and larger lung metastases. Our data suggest that CN/NFAT
signaling contributes to the maintenance of fibroblast homeostasis and that loss of CN/NFAT signaling is
sufficient to promote fibroblast activation, leading to the outgrowth of lung metastases. With a better
understanding of how CN affects fibroblast homeostasis, new therapeutic targets may be identified that
prevent the priming of the metastatic niche.
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ABSTRACT

THE ROLE OF CALCINEURIN/NFAT SIGNALING IN FIBROBLAST
HOMEOSTASIS AND ACTIVATION
Allyson Lieberman
Dr. Ellen Puré and Dr. Sandra Ryeom
Fibroblast activation is a crucial step in tumor growth and metastatic progression; activated
fibroblasts remodel extracellular matrix (ECM) in primary tumor and metastatic
microenvironments, exerting both pro- and anti-tumorigenic effects. However, the intrinsic
mechanisms that regulate the activation of fibroblasts are not well defined. The signaling
axis comprising the calcium-activated Ser/Thr phosphatase calcineurin (CN), and its
downstream target nuclear factor of activated T cells (NFAT), has been shown to play
important roles in in endothelial and immune cell activation, but its role in fibroblasts is
not known. We have shown that deletion of CN in fibroblasts in vitro results in alterations
in fibroblast morphology and function consistent with an activated phenotype relative to
wild-type fibroblasts. CN-null fibroblasts have greater migratory capacity, demonstrate
increased collagen secretion and remodeling, and promote more robust endothelial cell
activation in vitro. ECM generated by CN-null fibroblasts contain more collagen with
greater alignment of fibrillar collagen compared to wild-type fibroblast-derived matrix.
These differences in matrix composition and organization impose distinct changes in
morphology and cytoskeletal architecture of both fibroblasts and tumor cells that may
represent changes in their biological function, e.g. activation or epithelial-mesenchymal
transition. However, while they are more activated at baseline, Cn-/- fibroblasts cannot
iv

functionally respond to TGF-b stimulation in multiple activation assays. They are also
unable to upregulate FAP on soft, fibronectin-coated substrates to the same extent as WT
fibroblasts. Consistent with this in vitro phenotype, we show that mice with stromal CN
deletion exhibit a greater incidence and larger lung metastases. Our data suggest that
CN/NFAT signaling contributes to the maintenance of fibroblast homeostasis and that loss
of CN/NFAT signaling is sufficient to promote fibroblast activation, leading to the
outgrowth of lung metastases. With a better understanding of how CN affects fibroblast
homeostasis, new therapeutic targets may be identified that prevent the priming of the
metastatic niche.
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CHAPTER 1: GENERAL INTRODUCTION

Metastatic disease is responsible for 90% of total cancer deaths1; despite significant
advances in cancer treatment over the past few decades, the 5-year survival rate of patients
whose tumors have metastasized to distant organ sites is still much lower than that of
patients whose tumors have not spread2. Given that most cancers have likely already spread
at the time of diagnosis3, it is of utmost importance that metastatic disease be further
investigated, and new targets identified.
There have been many efforts to identify specific factors or signaling pathways in
tumor cells in order to better target tumor cells and successfully prevent and/or treat
metastases. However, these modalities are often complicated by the fact that the increased
proliferation and mutation rates of cancer cells facilitate the development of resistance to
targeted therapies4. Thus, the tumor microenvironment (TME) has become an increasingly
appealing target of study. The concept that the surrounding microenvironment might affect
a tumor cell’s ability to colonize and grow in a certain tissue has existed since 1889, when
the surgeon Dr. Stephen Paget hypothesized that metastatic growth in a specific organ
requires both the “seed,” the tumor cell, as well as the “soil,” a permissive
microenvironment5. It is increasingly clear, too, that the microenvironment of the distant
site is “primed” for metastasis prior to metastatic colonization6. Since Dr. Paget’s original
hypothesis, numerous studies have characterized the role of different cellular
compartments of the microenvironment – the blood and lymphatic vasculature, the immune
system, and the stroma – in tumor growth and progression (Figure 1.1). These findings
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have led to the development of a number of therapies targeting the microenvironment with
varying degrees of success.

Figure 1.1: Overview of the three major compartments of the tumor microenvironment and
their roles in tumor growth and progression.

The microenvironment is crucial to tumor growth and progression
The endothelium, angiogenesis and tumor growth
Blood and lymphatic vessels are crucial in tumor formation, as tumor cells are
rapidly growing and highly metabolically active, requiring a large amount of oxygen and
nutrients to support their growth. As they grow, the metabolic demand of tumors quickly
outstrips their vascular supply, which leads to intratumoral hypoxia and acidosis. These
changes in turn trigger blood vessel formation via the activation of hypoxia inducible
factors (HIF); this induction of angiogenesis is often referred to as the “angiogenic
switch7.” However, the constant, pathologic activation of angiogenic pathways without a
resolution phase leads to the formation of abnormal blood vessels; tumor vasculature is
2

often characterized by its increased vascular permeability (i.e. leakiness) and irregular
architecture when compared to normal vasculature8. This increased, abnormal
angiogenesis originally made it an appealing target for cancer drug development.
Some anti-angiogenic therapies have shown efficacy in specific cancer types, but
by and large, efforts to target tumor vasculature have not been as successful as initially
hoped. Anti-VEGF antibodies have been approved for use as a first-line therapy in only a
small number of cancers, including glioblastoma multiforme, colon cancer, and renal
carcinoma. Although anti-angiogenic therapies often lead to an increase in progressionfree survival, their effects on overall survival are significantly more modest or nonexistent,
and discontinuation of the drug may lead to “rebound vascularization” and subsequent
worsening of tumor growth9,10. The use of anti-VEGF therapy is also complicated by
significant adverse effects, including gastrointestinal perforation, thrombosis, and
hypertension11.

The immune system and immune surveillance
Equally important, and a current topic of particular interest in cancer therapeutics,
is the immune system. In order for tumors to grow, they must evade immune surveillance
despite an overall increase in inflammation, inflammatory cytokines, and tumor infiltrating
lymphocytes. This is accomplished through a variety of mechanisms. First, they can
downregulate the antigens they process and present, thus avoiding detection by immune
cells. Tumors can also induce the recruitment of suppressive immune cells such as
regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC) by secreting anti3

inflammatory cytokines, or by expressing inhibitory ligands that suppress T cell
activation12.
Two main strategies are currently being investigated to take advantage of the
immune system in cancer therapy: immune checkpoint inhibitors and engineered T cells.
The use of immune checkpoint blockade via CTLA-4, PD-1, or PD-L1 inhibitors seeks to
re-activate tumor cell-reactive T cells by blocking their regulatory signals13. Checkpoint
inhibitors have recently been approved for use in metastatic melanoma, prostate, lung, and
pancreatic cancers, among others and have shown efficacy; their use in other cancer types
is currently being investigated12. The second immune therapy currently under extensive
development is the use of chimeric antigen receptor-expressing T cells (CAR-T cells), in
which a patient’s T cells are virally transduced with a chimeric antigen receptor that directs
cell killing to an antigen of interest, then re-introduced to the patient. Currently, CD19specific CAR-T cell therapy is in use for patients with B cell malignancies (leukemia and
lymphoma), with many patients achieving complete and durable remission14. However,
clinical trials utilizing a wide variety of tumor antigens are underway, with varying degrees
of success and side effect profiles based on the tumor antigen used15. While CAR-T cells
appear to be a promising and powerful tool in cancer treatment, they are limited to cancers
with a targetable, surface-expressed tumor antigen that is broadly expressed across tumor
cells while being specific enough to prevent significant off-target effects.

The tumor-associated stroma
The third main component of the microenvironment, and the focus of my thesis
project, is the stroma, a term that encompasses the structural component of an organ or
4

tissue broadly consisting of extracellular matrix (ECM), the blood vessels/nerves supplying
the organ, and several cell types such as fibroblasts, pericytes, and certain immune cells.
The stroma is of particular interest as it undergoes marked changes upon tumor initiation
and progression that can be both pro- and anti-tumorigenic16. These will be discussed in
further detail in later sections; tumor-associated stroma is generally characterized by
increases in and re-organization of ECM, an increase in cell density consisting primarily
of fibroblasts and immune cells, and an overall pro-inflammatory milieu.
The stroma supports tumor cell growth and invasion, but it also participates in
significant crosstalk with the immune and endothelial compartments of the
microenvironment. Cancer-associated fibroblasts have been shown to alter the immune
system in ways that both promote and suppress tumor growth, through both direct
interactions with immune cells as well as secretion of a number of pro- and antiinflammatory cytokines17. Depletion of aSMA+ myofibroblasts in a mouse model of
pancreatic cancer decreased immune surveillance by increasing the number of intratumoral
regulatory T cells, ultimately resulting in greater invasiveness and mortality18. Recent work
in breast cancer identified four distinct subsets of CAFs with opposing effects on tumor
immunity and demonstrated differential accumulation of each of these populations in
different subtypes of breast cancer19.
Similarly, fibroblasts have been shown to enhance angiogenesis in both in vitro coculture assays as well as in murine models of tumor growth20,21. Fibroblasts can support
angiogenesis via a number of mechanisms, including upregulation of pro-angiogenic
factors such as HGF or VEGF22,23, downregulation of anti-angiogenic factors such as
5

thrombospondin-124,25, and deposition/remodeling of extracellular matrix26,27. While
tumor-associated, proliferative fibroblasts are considered to be pro-angiogenic, some
evidence suggests that fibroblasts may switch to an anti-angiogenic secretory phenotype as
they become quiescent in the setting of serum depletion28.
These interactions with other components of the microenvironment have important
implications for cancer therapeutics. For example, targeted deletion of FAP+ activated
fibroblasts has been shown to potentiate the response to anti-PD-L1 immunotherapy in
pancreatic cancer in a CXCL-12-dependent manner, suggesting that the stroma is partially
responsible for resistance to these therapies29. The stroma has also been implicated in
resistance to anti-angiogenic therapy, both via the secretion of pro-angiogenic factors as
well as deposition of matrix proteins such as periostin30,31.
Currently, clinically approved treatments exist that target or co-opt the endothelium
and immune system. However, drugs targeting the stroma are less well developed, though
several clinical trials are in progress. Thus far, attempts to target cancer-associated
fibroblasts (CAFs) have fallen into two categories: inhibiting their enzymatic function and
eliminating them entirely. Unfortunately, however, inhibitors targeting several markers of
activated fibroblasts, including fibroblast activation protein (FAP) and matrix
metalloproteinases (MMPs), have shown little to no clinical efficacy despite promising
results in mouse models32,33. Depleting tumors of cancer-associated fibroblasts has shown
some promise in preclinical studies and is currently being tested clinically. We and others
have designed CAR-T cells specific for CAF surface markers such as FAP, and studies in
mouse models of pancreatic cancer show that depletion of activated fibroblasts disrupts the
desmoplastic response and can improve chemotherapeutic efficacy34. However, the
6

heterogeneity of cancer-associated fibroblasts means that not all CAFs will be eliminated;
identifying the most influential subpopulation of fibroblasts in a particular cancer will be
crucial to the success of this treatment modality.
Additionally, activated fibroblasts play a key role in the maintenance of normal
tissues, and targeting CAFs may have significant side effects. One method of reducing offtarget toxicity is to select an activated fibroblast marker such as FAP that is minimally
expressed in normal tissues in order to minimize effects on normal tissue35,36. Our lab has
shown that targeting FAP+ cells using CAR-T cells causes only minimal off-tumor
toxicity37. That having been said, one study in mice demonstrated that depletion of FAP+
stromal cells in mice led to significant cachexia and anemia due to the prevalence of these
cells in normal skeletal muscle and bone marrow38. Even if normal tissues at baseline are
relatively unaffected by these therapies, targeting activated stroma may lead to an inability
for tissues to respond to external stressors. While activated fibroblasts play an important
role in pathologic processes such as tumor growth and fibrosis, they are also crucial to
physiologic processes such as wound healing and normal tissue remodeling39,40. In diseases
such as cancer, which can be managed both surgically and medically, targeting of activated
fibroblasts may lead to increased surgical morbidity due to alterations in inflammation and
wound healing.
There is also interest in targeting the ECM itself; current studies have focused on
pancreatic cancer, a cancer type known for its significant desmoplasia. Excessive amounts
of hyaluronic acid lead to high interstitial fluid pressure within the tumor, in turn limiting
chemotherapeutic accessibility. Consequently, treatment of in vivo mouse models of cancer
with a pegylated form of hyaluronidase (PEGPH20) increases the efficacy of chemotherapy
7

and improves tumor response41. Clinical trials of PEGPH20 in patients with advanced
hyaluronan-high pancreatic cancer are currently underway and show promise in terms of
response rate and progression-free survival42. However, this treatment will only have
significant effects in hyaluronan-dense tumors, meaning that it will be ineffective in a large
number of cancers.
Targeting the stroma is an attractive target because of the potential to be widely
applicable across multiple cancer types; however, much research still needs to be done for
these targeted therapies to be effective. One of the reasons that stroma-targeting therapies
have only been partially successful thus far is because the mechanisms informing the
activation and formation of tumor-associated stroma are not well understood in comparison
to the endothelium and immune system. While many activating stimuli have been
identified, and the changes in activated stroma characterized, the molecular mechanisms
causing stromal activation are largely unknown. Thus, previous therapeutic efforts have
focused primarily on targeting specific surface markers or extracellular matrix components
as opposed to blocking or reversing the activation of the stroma itself. To deprogram
activated, cancer-associated stroma effectively requires a better understanding of how it is
activated in the first place. I will next briefly review and discuss what is known regarding
the two major components of the stroma: the extracellular matrix and the fibroblasts that
secrete and remodel it.

The extracellular matrix
The extracellular matrix is a hydrogel that consists of a variety of matrix proteins,
proteoglycans, and polysaccharides organized in a way that lends structure to the organ or
8

tissue it supports (Table 1.1). Two main types of ECM exist in tissues: the basement
membrane, which largely consists of type IV collagen and serves as a barrier and basal
layer for epithelial cells, and the interstitial ECM, which provides a supportive medium
between cells in a tissue43. Together, these form a scaffold and provide anchoring points
for the numerous cell types and structures within an organ.
One of the most abundant components of the interstitial ECM is collagen,
specifically the fibrillar collagens such as types I, II, III, and VI44. Collagen is secreted in
an immature form and must undergo multiple proteolytic processing steps and posttranslational modifications in order to form mature collagen fibrils44,45. Crosslinking of
collagen fibrils is crucial to the overall architecture of collagen; large amounts of crosslinks
lead to the linearization of collagen fibers, a process that is often mediated by proteins such
as lysyl oxidase (LOX)44. Once mature fibrils have been established, they can be
proteolytically processed by the collagenase family of matrix metalloproteinases such as
MMP1 and MMP8, whereas denatured collagen is processed by the gelatinases such as
MMP2 and MMP9; this processing can degrade collagen, release bioactive fragments, or
help to change its architecture and re-orientation46. We have also shown that FAP is capable
of cleaving fibrillar collagen, but only after it has been processed into ¼ and ¾ fragments
by collagenases such as MMP147. Apart from collagen, other abundant macromolecules in
the interstitial ECM include fibronectin, tenascin C, hyaluronic acid and other
glycosaminoglycans, and periostin43. There are significant interactions between different
matrix proteins; for example, collagen binds to fibronectin and increases its rigidity, thus
improving the affinity of fibronectin for its receptors44.
9

Components of Interstitial ECM
Fibrillar collagens (I, II, III, V, VI, XI, XXIV,
XXVII)
Fibronectin
Elastin
Laminin
Hyaluronic acid
Tenascin C
Periostin
Proteoglycans (heparan, chondroitin, keratan
sulfate)
Fibrin
Table 1.1: Common components present in
interstitial extracellular matrix.

Apart from its roles in tissue integrity and architecture, the ECM is crucial to
cellular function within a tissue by transducing signals through several methods. First, the
organization and composition of the matrix informs its mechanical stiffness, and this
stiffness in turn can activate signaling pathways such as FAK and YAP/TAZ in a number
of cell types, including fibroblasts48. The matrix proteins themselves can engage cell
surface receptors, most notably integrins. The binding of matrix components to integrins
can differ depending on the size of the matrix fragment or its conformation; one major
example is the increased affinity of integrin a1b1 to monomeric over mature fibrillar type
I collagen, implicating its role in early collagen fibrillogenesis49. This allows the ECM to
inform cell signaling based on its structural properties44,50. Finally, the ECM can be a
source of growth factors, cytokines, and chemokines. Matrix proteins can sequester certain
growth factors by binding to them; these growth factors can then be released upon
proteolysis of the matrix51. Further, proteolytic processing of the matrix can release
bioactive fragments of the matrix itself. One such example is endostatin, which is a C
terminal fragment of type XVIII collagen with substantial anti-angiogenic properties52.
10

The ECM plays many crucial roles in disease processes such as fibrosis and cancer.
In most solid tumors, the matrix undergoes several changes over the course of tumor
progression, transitioning from a fibrin- and fibronectin-rich “provisional matrix” to a
desmoplastic, fibrillar collagen-rich environment53. One of the ways this progressive
remodeling of ECM can be identified is via tumor-associated collagen signatures (TACS),
which were first defined in mammary tumor progression (Figure 1.2). TACS-1,
corresponding to pre-malignant lesions, represents an increase in total collagen signal.
TACS-2, seen in early tumor growth, occurs when these collagen fibers begin to linearize,
oriented parallel to the tumor boundary and constraining the edges of the tumor, due to a
combination of proteolytic processing, crosslinking, and contractile forces exerted by
tumor-associated fibroblasts. Finally, TACS-3, observed in invasive cancers, occurs when
these linear collagen fibers become re-oriented in a perpendicular fashion to the tumor
boundary54. These alterations in collagen architecture have been shown to have both proand anti-tumorigenic properties. TACS-3-like collagen signatures are thought to
specifically promote invasion: in tumor tissues, these linear, perpendicular collagen fibers
serve as a scaffold along which invasive tumor cells can escape and enter the interstitium55.
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Figure 1.2: Tumor-associated collagen signatures (TACS) during
tumor progression. Reproduced from Malik et al, Trends Biotechnology
2015.

Fibroblasts are a key component of the stroma and are activated in both physiologic
and pathologic states
Fibroblasts are the cell type in the microenvironment that is primarily responsible
for secreting and remodeling ECM in both normal and diseased tissues. They have been
identified as key mediators of many of the phenotypes present in tumor-associated stroma,
specifically via their activation. Fibroblasts are cells of mesenchymal origin; one difficulty
inherent in their study is the fact that no one universal and specific marker defining the
fibroblast population has yet been identified, unlike, for example, CD31 in endothelial
cells. Fibroblasts are known to express vimentin due to their mesenchymal origin, as well
as CD90/Thy1; however, neither of these markers is specific to fibroblasts and must be
used in combination with other markers such as CD45 as well as contextual clues, i.e. their
location in a specific tissue. Despite its name, the expression of fibroblast-specific protein
1 (FSP1)/S100A4 is not limited to fibroblasts, as it has been observed to be expressed in a
12

variety of cell types, including hematopoietic cells, endothelial cells, and vascular smooth
muscle cells56. On the other hand, markers such as fibroblast activation protein (FAP) and
alpha-smooth muscle actin (aSMA) are generally expressed only by activated fibroblasts,
which omits a large percentage of fibroblasts in tissue. Due to the lack of a universal
fibroblast marker, the isolation of fibroblasts is generally performed through a functional
property, by selection for adherent cells, and are characterized by their spindle-shaped
morphology in combination with one or more of the markers described above57.
The majority of tissue-resident fibroblasts are quiescent and un-activated, with the
exception of dermal fibroblasts, which express a small amount of FAP at baseline. Tissueresident fibroblasts generally have very low proliferation rates and may contribute to a
small amount of baseline ECM secretion and remodeling, but they are otherwise relatively
mitotically and transcriptionally inactive57. When these quiescent fibroblasts are exposed
to disease-related stimuli, however, they undergo a process of activation that leads to
drastic changes in their function. Before describing the phenotypes associated with
fibroblast activation, it is important to note that activated fibroblasts represent a
heterogeneous population. Some of this may be due to the fact that they have multiple
cells/tissues of origin58. In addition, gene expression-related profiling often reveals a large
number of distinct, yet overlapping, cell populations that fall under the category of
activated fibroblasts59. Cancer-associated fibroblasts have proven to be a particularly
heterogeneous population, with studies revealing many distinct subpopulations of
fibroblasts in a variety of cancers60–63. Thus, when considering activated fibroblasts, it is
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important to profile a variety of their functions to determine the specific functional
phenotypes they represent.
Fibroblast activation is functionally defined by several changes (Figure 1.3). Given
their heterogeneity, activated fibroblasts can exhibit one or many of these changes, and
specific subpopulations often select for a specific subset of these functions. They can
increase their proliferation, thus at least partially accounting for the increased number of
fibroblasts seen in diseased tissues. They undergo cytoskeletal reorganization and a change
in morphology; their migratory capacity increases dramatically. They deposit large
amounts of ECM, especially collagen, and remodel existing matrix, leading to reorientation of collagen fibers. Finally, they secrete a wide variety of cytokines,
chemokines, and other molecules that can have effects on immune, endothelial, and tumor
cells as well as having autocrine effects to amplify fibroblast activation57,64,65.

Figure 1.3: Schematic of the activation and function of fibroblasts in pathologic and
physiologic states. Adapted from Kanasaki et al, Frontiers in Endocrinology 2013.

Fibroblast activation plays a critical role in a variety of both physiologic and
pathologic processes. In normal wound healing, dermal fibroblasts transdifferentiate into
myofibroblasts in order to assist in wound closure and remodel the matrix in the developing
14

scar66. When this process is deregulated, it can lead to the development of keloid scars,
benign hyperproliferative lesions that are difficult to treat, have a high recurrence rate, and
can significantly negatively affect quality of life. Histologic analysis of keloid scar tissue
demonstrates an increase in fibroblast proliferation, extracellular matrix production, and
invasion into surrounding healthy tissue compared to normal wound healing. Further,
evidence suggests that FAP may be crucial to the development of keloids by promoting
invasiveness in keloid fibroblasts67. Apart from their role in dermatologic processes,
activated fibroblasts also play an important role in the initiation and progression of fibrotic
disease in a variety of organs, including the lung, liver, and kidneys. Activated fibroblasts
in the tumor microenvironment, often called cancer-associated fibroblasts (CAFs) in this
setting, are major contributors to tumor progression and metastasis. Tumors have often
been described as “wounds that do not heal” due to the fact that much of the tumor stroma
closely resembles that of healing wounds that, unlike normal wound healing, do not resolve
over time53. In the setting of cancer and metastasis, activated fibroblasts are generally
considered to be pro-tumorigenic; conversely, normal fibroblasts can be tumorpreventative, thus making fibroblast activation a requirement for tumor progression68,69.
A wide variety of fibroblast-activating stimuli have been identified. These can be
separated into several sub-groups: mechanical forces such as elastic stretching or changes
in substratum stiffness; secreted factors and cytokines such as TGF-b, PDGF, and IL-6;
ECM composition and contents of the substratum; and cellular stress/damage such as
reactive oxygen species (ROS)57. Of note, different stimuli may also select for specific subpopulations of activated fibroblasts. Our lab has previously shown that the levels of FAP
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and aSMA differ greatly depending on which growth factors and/or chemokines are added;
furthermore, alterations in the content and/or stiffness of the ECM are sufficient to direct
pulmonary fibroblasts toward either a FAP+, secretory fibroblast state, or an aSMA+,
myofibroblast state60.
Though the activating stimuli of fibroblasts have been well-profiled, the molecular
mechanisms that underlie fibroblast activation are less well known. A number of signaling
pathways, especially those downstream of the ligands Notch and Sonic hedgehog (Shh),
have been of particular recent interest in the modulation of the CAF phenotype57. Lossand gain-of-function studies have identified the epithelial-to-mesenchymal transition
marker Twist1 as crucial to the function of pancreatic cancer-associated fibroblasts70.
While many of these signaling pathways have been shown to be sufficient to induce a CAFlike state, it is unclear which of these mechanisms are specifically required for fibroblast
activation.

Fibroblast quiescence: how the un-activated state is maintained
Current understanding of cell quiescence argues that it is not a dormant or default
state but rather an active cell state that requires maintenance. As opposed to irreversible
dormant states, quiescence must be quickly reversible, which requires that the cell be
primed for re-entry into a more transcriptionally active and/or proliferative state.
Homeostasis often involves the maintenance of a specific biologic value (e.g. gene
expression levels) within a certain range and not necessarily at a fixed point, a process
requiring the constant expression and function of molecular sensors71. Furthermore, in
order for cells to exit the homeostatic steady state, they must achieve a certain “activation
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energy” that allows them to enter an unstable transition state prior to activation,
differentiation, and/or proliferation72. Cellular homeostasis and quiescence have been
studied extensively in stem cells, a cell type in which the maintenance of the quiescent,
undifferentiated state is crucial to proper tissue renewal. The loss of homeostatic regulators
of hematopoietic stem cells, such as folliculin, leads to bone marrow failure due to
uncontrolled differentiation and lack of self-renewal, suggesting that the “energy barrier”
to differentiation maintained by this regulator is removed73.
Compared to many other cell types, fibroblasts exhibit significant phenotypic
plasticity and are able to tightly regulate the transition between multiple cellular states
throughout disease progression74. This plasticity suggests that the “quiescent state” of
tissue resident fibroblasts may in fact represent a steady state of constant, dynamic changes
in gene expression, contractility, and motility. One study examining the forces exerted by
spreading fibroblasts on a fibronectin substrate demonstrated that fibroblasts have the
ability to maintain tensional homeostasis within a specific range via “tensional buffering,”
a process in which fibroblasts exert variable forces on the substrate in order to maintain
steady state tension75. Quiescent fibroblasts exhibit significant levels of metabolic activity
despite their relatively low transcriptional activity, suggesting that fibroblast quiescence is
actively maintained76. Interestingly, some evidence suggests that quiescent fibroblasts may
be more capable of promoting inflammation, as measured by greater levels of
cyclooxygenase-2 expression in response to IL-1b stimulation, compared to proliferating
fibroblasts77.
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The mechanisms that maintain the quiescent, un-activated state in tissue-resident
fibroblasts are still largely unknown. Few markers that specifically delineate the quiescent
fibroblast state versus the activated fibroblast have been identified; an un-activated
fibroblast is most frequently defined by its lack of activated fibroblast-associated markers
and functions. A 2016 review of the role of fibroblasts in cancer suggested that FSP1 is a
specific marker of quiescent fibroblasts57; however, there is little to no literature evidence
to support this claim. One recent study used cell-surface phenotyping to identify CD36 and
CD97 as markers of quiescent lung fibroblasts; they showed that its expression in primary
lung fibroblasts was attenuated with TGFb-induced myofibroblast differentiation and did
not overlap with aSMA expression78.
There is some evidence that specific factors are capable of either maintaining
quiescence and/or blocking fibroblast activation. Prostaglandin E2 (PGE2) has several antifibrotic effects mediated by the multiple signaling pathways downstream of the Eprostanoid 2 receptor79–81. Additionally, secreted protein acidic and rich in cysteine
(SPARC) modulates myofibroblast differentiation and ECM secretion in response to TGFb, though its specific role in fibrotic disease is complex, encompassing both pro- and antifibrotic effects82–84. Alterations in substratum stiffness have also been shown to be
sufficient to “deprogram” myofibroblasts, transitioning from a more activated to a less
activated state. One group utilized polyacrylamide hydrogels whose stiffness could be
decreased by ultraviolet light-induced depolymerization. Valvular fibroblasts cultured on
stiff (32 kPa) hydrogels express aSMA and otherwise display a myofibroblast phenotype;
when these stiff hydrogels are softened via depolymerization, the fibroblasts cultured on
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them lose their aSMA expression and myofibroblast phenotype85. Notably, however, we
have shown that fibroblasts initially cultured on 20-25 kPa (stiff) polyacrylamide hydrogels
and passaged onto 2-5 kPa (soft) hydrogels switch from an aSMAhi to a FAPhi phenotype,
suggesting that a decrease in mechanical stiffness to a less pathologic but still
supraphysiologic value alters the phenotype of fibroblasts to a non-myofibroblast but still
functionally activated state. This suggests that the loss of myofibroblast markers observed
upon UV-induced depolymerization may not represent complete deprogramming but
instead a shift in their activated fibroblast phenotype. Finally, several studies have
identified small molecule inhibitors capable of preventing fibroblast activation.
Nintedanib, a multikinase inhibitor that has been approved for use in non-small cell lung
adenocarcinoma, is capable of blocking TGF-b1-induced myofibroblast differentiation and
pro-tumorigenic function in tumor-associated fibroblasts86,87. The drug Minnelide has also
been shown to inhibit fibroblast activation in the setting of PDAC through mechanisms
that are currently incompletely defined88.
While anti-fibrotic factors and drugs have been identified, little is known about the
molecular mechanisms that maintain the quiescent fibroblast phenotype. It is clear that the
quiescent fibroblast state consists of more than a simple arrest in proliferation, and the
fibroblast-intrinsic processes that actively maintain their quiescence in terms of functional
activation are not well defined. The tumor suppressor p53 has been shown to play an
important role in the tumor suppressive effects of normal fibroblasts; however, p53regulated transcription is drastically changed in cancer-associated fibroblasts, instead
supporting the CAF phenotype89. Some signaling pathways have been found to be
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downregulated in CAFs in certain cancers; the Notch effector CBF1, Suppressor of
Hairless, Lag-1 (CSL) has been shown to regulate fibroblast homeostasis through direct
interactions with p5390. In many dermatologic malignancies, CSL activity, and
subsequently fibroblast quiescence, is reduced via the downregulation of androgen
receptor, which interacts with CSL in order to restrain the activation of CAFs through
transcriptional repression91. Cellular quiescence in fibroblasts may also rely on paracrine
signaling from other compartments of the microenvironment, particularly normal
epithelium92.

Calcineurin/NFAT: a signaling axis responsible for both activation and quiescence
in a number of cell types
One signaling pathway that has been implicated in several cell types in the tumor
microenvironment is the axis consisting of calcineurin (CN) and its canonical targets, the
nuclear factor of activated T cells (NFAT) family of transcription factors (Figure 1.4).
CN/NFAT was first identified as a regulator of T cell activation but has since been shown
to play a role in a variety of cell types. CN is a calcium-regulated serine-threonine
phosphatase that consists of two subunits: a catalytic (calcineurin A) and a regulatory
subunit (calcineurin B)93. Upon increased calcium flux into the cytoplasm, calcineurin is
activated through a conformational change, exposing its catalytic site. The best-known
substrates of CN are the NFAT family of transcription factors, which translocate to the
nucleus upon their dephosphorylation by CN and transactivate tissue-specific genes. NFAT
exists in 4 canonical isoforms, known as NFAT1-4 or NFATc1-4. NFAT5 shares
homology with the other NFAT isoforms but is not activated by calcineurin. All NFAT
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isoforms alone display weak DNA-binding capabilities; thus, they require a more strongly
DNA-binding

transcriptional

co-activator

or

co-repressor

for

effective

signal

transduction94.

Figure 1.4: Simplified diagram of the calcineurin/NFAT
signaling axis.

CN signaling has been shown to play a crucial role in both tumor cells and their
microenvironment. Interestingly, individuals with Down syndrome, who due to trisomy 21
have 3 copies of the endogenous CN inhibitor Down syndrome critical region 1 (DSCR1),
have a lower incidence of solid tumors than the general population, though they have a
higher incidence of leukemias95–97. This is thought to be due to decreased angiogenesis
secondary to an increase in inhibition of the calcineurin-mediated response to VEGF
signaling, as well as increased inhibition of calcineurin leading to impaired cell cycle
progression and, consequently, tumorigenesis98–100. On the other hand, transplant patients
receiving cyclosporine A (CsA) or other calcineurin inhibitors such as tacrolimus have an
increased risk of malignancy; conversely, this is generally thought to be due to a decrease
in tumor immune surveillance101. These clinical findings have led to a large amount of
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research ultimately demonstrating that CN/NFAT signaling plays a crucial role not only in
tumor cells themselves100,102,103 (most likely in an NFAT isoform-specific manner99), but
in many cell types in the microenvironment as well94. Our lab has previously shown that
activation of CN/NFAT in the endothelium is a crucial step in the priming of the lung as a
distant metastatic site104. At the same time, we have shown that genetic deletion of Dscr1
suppresses tumor growth due to dysregulation of apoptotic ligands and subsequent
endothelial apoptosis, suggesting that excessive calcineurin signaling can instead limit
tumor growth (Figure 1.5)105.

Figure 1.5: The proliferative response to calcineurin
signaling in endothelial cells follows a U-shaped curve.
Reproduced from Ryeom et al, Cancer Cell 2008.

While calcineurin’s role in tumor cells, immune cells, and the endothelium are
fairly well-characterized, little work has been done to study the effect of CN/NFAT
specifically in cancer-associated fibroblasts. Previous studies examining the role of
CN/NFAT in fibroblasts have identified both pro- and anti-fibrotic effects of CN signaling.
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Long-term treatment of transplant patients with the calcineurin inhibitors cyclosporin A
(CsA) and/or tacrolimus is often complicated by acute and chronic nephrotoxicity, of which
tubulointerstitial fibrosis is a hallmark106–108. Further, CsA has been shown to have direct
fibrogenic effects on renal tubulointerstitial cells and fibroblasts109, and deletion of the a
isoform of CnA is sufficient to cause renal fibrosis and increased fibronectin and TGFb
expression in renal fibroblasts110. However, other studies have shown that downregulation
of CN/NFAT signaling via pharmacologic inhibition or genetic deletion leads to a decrease
in fibrosis-associated phenotypes in cardiac111,112, dermal113, and lung114 fibroblasts.
Additionally, many of these studies utilized CsA to inhibit CN, and we and others have
shown that CsA has a number of calcineurin-independent targets and effects115,116. For
example, CsA has been shown to attenuate disease progression in a bleomycin model of
murine lung fibrosis; however, this effect was demonstrated to be independent of
calcineurin signaling, as administration of tacrolimus did not recapitulate this phenotype117.
In summary, fibroblast activation is a crucial process in both physiologic and
pathologic states, but the molecular mechanisms mediating their activation are not fully
defined, and very little is known regarding the mechanisms maintaining their quiescence.
There is some previous evidence that CN/NFAT signaling may play a role in fibroblast
activation, but the current data is conflicting, and results are often confounded by the
significant off-target effects of pharmacologic inhibition of CN. Therefore, the goal of my
thesis project was to fully investigate the role of CN/NFAT signaling in fibroblast
activation in the setting of the lung. By studying the phenotype of the CN-null pulmonary
fibroblast in vitro and in vivo, we identified how CN specifically mediates the homeostasis
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and activation of fibroblasts, and how this phenotype may affect disease states such as
cancer.
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CHAPTER 2: DELETION OF CALCINEURIN PROMOTES A PROTUMORIGENIC FIBROBLAST PHENOTYPE.

Introduction
The tumor microenvironment (TME) consists of multiple cell types, including
endothelial, immune, and stromal cells118. It is instrumental in the development of both
primary tumors and distant metastases, making it an appealing potential therapeutic target.
Fibroblasts, a key component of the stroma, are cells of mesenchymal origin that play a
number of roles in both normal and diseased tissues. Resident fibroblasts can orchestrate
and maintain the architecture of extracellular matrix (ECM) in normal tissues, but
activation of fibroblasts is crucial to dynamically remodel the matrix in both physiologic
processes such as wound healing as well as pathologic processes such as fibrosis and
cancer119. Studies have indicated that normal tissues are resistant to tumor cell colonization
and growth due in part to fibroblast homeostasis, and that fibroblast activation is required
for both primary tumor progression and metastatic colonization119,120. While multiple
stimuli that contribute to the activation of fibroblasts have been identified, the cell-intrinsic
molecular mechanisms underlying the transition from quiescent to activated fibroblasts, or
the “stromagenic switch,” are less well understood.
The most widely used markers of activated fibroblasts currently include fibroblast
activation protein (FAP)121,122 and the myofibroblast marker alpha-smooth muscle actin
(aSMA)123. Expression of these and other markers indicate they represent heterogeneous
populations with unique gene expression profiles dependent on both context and tissue of
origin124. However, collectively, activated fibroblasts can increase their migration and
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contractility, secrete and remodel extracellular matrix, including collagen, and produce
cytokines and growth factors that affect other cellular compartments in the
microenvironment such as the immune system and the endothelium. A variety of stimuli
are responsible for fibroblast activation, including changes in substratum mechanical
stiffness, composition and architecture of the ECM, growth factors such as TGFb or PDGF,
cytokines and chemokines, and sources of cellular stress such as hypoxia or ROS125.
While many of the activating stimuli of fibroblasts and their downstream mediators
of activation have been well-defined, less is known about cell-intrinsic pathways required
to maintain the homeostatic state of resident un-activated fibroblasts. It is increasingly
evident that quiescence is not simply a default state but rather requires active maintenance;
however, little is known about the intracellular signaling pathways responsible for
maintaining homeostasis71. The calcineurin (CN)/nuclear factor of activated T cells
(NFAT) signaling pathway was originally identified as critical for T cell activation and has
since been shown by us and others to also play key roles in numerous other cell types,
including endothelial cell activation and tumor angiogenesis95,104,105. CN is a calciumregulated serine-threonine phosphatase that consists of two subunits: a catalytic
(calcineurin A) and a regulatory subunit (calcineurin B)93. Upon increased calcium flux
into the cytoplasm, calcineurin is activated through a conformational change, exposing its
catalytic site. Its best-known substrates are the NFAT family of transcription factors, which
translocate to the nucleus upon their dephosphorylation by CN and transactivate tissuespecific genes. We previously demonstrated that the CN/NFAT pathway plays a key role
in mediating endothelial cell activation downstream of VEGF, and that pharmacologic or
genetic deregulation of CN signaling affects both primary tumor growth and metastatic
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progression95,104,105. Prior studies by others have shown contrasting effects of the CN
pathway in activated fibroblasts, with reports of both pro- and anti-fibrotic effects of CN
in vitro and in vivo37-45. Moreover, to our knowledge, the role of CN/NFAT in fibroblasts
in the TME has not yet been investigated.
As the CN/NFAT pathway has been implicated in regulating the function of
multiple cell types in the TME94, as well as in fibroblast activation in wound healing and
fibrosis, we hypothesized that CN/NFAT may play a role in regulating the function of
fibroblasts in the TME. To test this hypothesis, we examined the role of CN signaling in
lung fibroblasts and assessed the impact of fibroblast-specific deletion of CN on lung
metastasis. Here we demonstrate that acute deletion of calcineurin in lung fibroblasts leads
to increased proliferation, migration, and contractility compared to wild-type fibroblasts,
changes consistent with activation. Furthermore, we found that extracellular matrix derived
from Cn-/- fibroblasts contains greater amounts and more linearly aligned fibrillar collagen,
and that Cn-/- fibroblasts support more robust endothelial cell tube formation in vitro.
Consistent with our in vitro findings, we found that stromal cell specific Cn deletion in
mice leads to a higher incidence and increased size of lung metastases in a spontaneous
lung metastasis model with two different tumor cell lines. Our findings implicate CN in
maintaining fibroblast homeostasis in normal, unstimulated states, and in attenuating the
pro-tumorigenic activity of fibroblasts in the metastatic niche.

Results
Calcineurin deletion in vitro promotes fibroblast migration
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To analyze the role of calcineurin in fibroblast activation in vitro, we treated
primary lung fibroblasts derived from calcineurin B (CnB) floxed mice with adenoviral
Cre recombinase. Deletion of CnB destabilizes and promotes proteolytic degradation of the
calcineurin A subunit126. Benign and malignant diseases, including wound healing,
fibrosis, and cancer, all feature increased numbers of fibroblasts that can be attributed to a
combination of fibroblast proliferation, migration of nearby resident fibroblasts to lesions,
and recruitment of mesenchymal precursors from the bone marrow. Thus, we first
examined whether acute deletion of CN altered fibroblast proliferation. We observed no
difference in cell proliferation between WT and Cn-/- fibroblasts (Figure 2.1A). However,
in scratch assays of confluent monolayers, Cn-/- fibroblasts exhibited enhanced closure at
24 hours post-wounding (Figure 2.1B), and live-cell imaging over the first 24 hours postscratch revealed that Cn-/- fibroblasts exhibited accelerated and markedly different
migratory phenotypes compared to WT fibroblasts. Specifically, Cn-/- fibroblasts migrated
oriented perpendicularly to the leading edge of the wound as compared to WT fibroblasts,
which exhibited more stochastic motion throughout wound closure (Supplemental Video
1).
The accelerated wound closure by Cn-/- fibroblasts in scratch assays suggested that
deletion of calcineurin might increase the migratory ability of fibroblasts. Indeed, we found
that in uncoated transwell migration assays, Cn-/- fibroblasts exhibited greater migration
compared to wild-type fibroblasts after 24 hours (Figure 2.1C). However, Cn-/- fibroblasts
exhibited impaired migration compared to WT controls on transwells coated with type I
collagen (Figure 2.1D), implicating an inability of calcineurin-null fibroblasts to invade
and migrate through a collagen matrix. Collectively, these data indicate that while CN
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deletion increased fibroblast migration, it inhibited collagen invasion and had no effect on
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As another key function of activated fibroblasts is to process and remodel collagen,

we plated fibroblasts onto thick type I collagen gels. In the absence of fibroblasts, these
collagen gels contain very little fibrillar collagen as visualized by 2-photon second
harmonic generation (SHG) imaging; once fibroblasts are added, they remodel and exert
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tension on the collagen substratum, leading to the formation of a network of collagen fibers
visible by SHG. Cn-/- fibroblasts remodeled type I collagen gels to a greater extent than WT
fibroblasts, leading to increased SHG signal (Figure 2.2A).
To further investigate the effects of CN deletion on collagen remodeling, we
utilized a collagen contraction assay, in which fibroblasts were embedded in a type I
collagen gel that was then detached and allowed to float freely in culture medium. When
the solidified collagen gels are detached, a combination of collagen remodeling and
fibroblast contractility exerts forces on the gel, causing it to contract127. CN deletion
significantly increased the rate of collagen gel contraction at 6 and 12 hours postdetachment with maximal contraction by 12 hours. In contrast, WT fibroblasts required
almost 20 hours post-detachment for maximal contraction (Figure 2.2B).
We assessed the ability of Cn-/- fibroblasts to deposit, accumulate and remodel
collagen by comparing fibroblast-derived matrices (FDMs) from WT and Cn-/- fibroblasts
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. We found that CN deletion led to significant increases in the accumulation of fibrillar

collagen and alignment of collagen fibrils as observed by SHG imaging (Figure 2.2C).
Extracellular matrix can be remodeled through multiple mechanisms, including the
production of collagenases by fibroblasts, so we compared the collagenase activity
associated with CN-null and WT fibroblasts by overlaying DQTM type I collagen on
fibroblasts cultured on collagen gels. DQ collagen is saturated with quenched fluorescein
molecules, and digestion by collagenases releases fluorescent fragments of collagen that
are visible by fluorescence microscopy. Cn-/- fibroblasts plated on either gelatin-coated
chamber slides or a collagen substratum exhibited greater collagenase activity than WT
fibroblasts (Figure 2.2D-E).
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Figure 2: Calcineurin-null fibroblasts exhibit increased collagen
contractility and matrix remodeling.
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Figure 2.2: Calcineurin-null fibroblasts exhibit increased collagen contractility and matrix
remodeling. A. Phase-contrast and 2-photon second harmonic generation (2P-SHG) images of WT and
Cn-/- fibroblasts cultured on collagen gels in serum-containing media for 48 hours. Total SHG signal
(green) was quantified using ImageJ and normalized to cell count as measured by autofluorescent signal
(white). Magnification bar = 250 µm. B. Representative images (after 6 hours) and quantification of
collagen contraction by WT and Cn-/- fibroblasts at indicated times. White dotted lines denote collagen
gel circumference. C. Representative 2P-SHG images of fibroblast-derived matrices. Total SHG signal
(green) was quantified using ImageJ, and collagen fiber alignment scores were determined using
CurveAlign software. Bar = 100 µm. D. Images from DQ collagen assay on gelatin-coated glass and
quantification of average DQ signal per nucleus using ImageJ. E. Images from DQ collagen assay on
type I collagen gels. Collagenase-digested DQTM collagen signal is green and nuclei (DAPI stain) are
blue. Bar = 250 µm. All samples were assayed in triplicate, N=2-5. *p<0.05, **p<0.01. Error bars =
standard deviation.
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This effect was specific for collagenase activity, as we observed no difference in gelatinase
activity under either culture condition (data not shown). Taken together, our data indicate
that CN deletion leads to an increase in collagen accumulation, remodeling, and
contractility in the absence of exogenous activating stimuli, suggesting that the calcineurin
pathway may be important for fibroblast homeostasis.

Calcineurin deletion leads to alterations in collagen processing consistent with a CAF-like
state
Given that higher fiber density and greater fiber alignment are characteristic of
FDMs derived from cancer-associated fibroblasts, we compared WT and Cn-/- fibroblastderived matrices generated in the presence of normal media or cancer cell conditioned
media (CM) from SR0144 cells, a murine lung adenocarcinoma cell line driven by loss of
Tp53 and expression of oncogenic Kras. As expected, when WT fibroblasts were cultured
with tumor CM, we observed a greater accumulation of fibrillar collagen in the generated
matrix as measured by SHG signal than in matrix generated by WT cells in normal media.
We also observed foci of more highly aligned collagen in FDMs generated by WT cells in
the presence of tumor CM. Interestingly, we found that FDMs generated by Cn-/- fibroblasts
in the presence of normal media also exhibited increased accumulation of fibrillar collagen
similar to that
2 seen in WT FDMs generated in tumor CM (Figure 2.3A). These data suggest
Cn-/- fibroblasts are phenotypically similar to tumor cell CM-treated WT fibroblasts and do
not respond to further stimulation by tumor CM.
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We decellularized and examined Cn-/- and WT FDMs at earlier timepoints to
determine differences in matrix deposition and remodeling. After 3 days, there were
noticeable differences in both fibroblast and matrix alignment in CN-null fibroblasts as
determined by phase contrast imaging, which were further enhanced after 5 days (Figure
2.3B). Consistent with the increase in linear alignment of collagen fibrils in FDMs derived
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Cytoskeletal reorganization in fibroblasts is regulated by calcineurin
Our data show that calcineurin regulates fibroblast-mediated matrix remodeling,
and it is well-established that alterations in matrix organization drive cytoskeletal
reorganization as well as cell size and shape. Thus, we compared how FDMs derived from
WT and CN-deleted fibroblasts affected reorganization of the actin cytoskeleton in
fibroblasts and/or tumor cells. When WT fibroblasts were plated on Cn-/- FDMs and stained
for phalloidin and the focal adhesion complex protein paxillin, they extended long, thin
cytoplasmic processes and demonstrated an elongated morphology compared to their
behavior on WT FDMs (Figure 2.4A). We also plated murine YFP-expressing pancreatic
ductal adenocarcinoma cells (PDAC) onto FDMs generated from WT and Cn-/- fibroblasts
and analyzed their cytoskeletal architecture via phalloidin staining and confocal
microscopy. Similar to the fibroblasts, PDACs cultured on FDMs derived from Cn-/fibroblasts were also elongated (Figure 2.4B), and live-cell imaging of PDACs on these
FDMs revealed greater displacement and more linear movement on Cn-/- FDMs as
compared to WT FDMs (Figure 2.4C-D, Supplemental Video 2). Therefore, the matrix
generated by Cn-/- fibroblasts is sufficient to significantly alter the cytoskeletal architecture
of both tumor cells and fibroblasts as compared to matrix derived from WT fibroblasts.
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Figure 4: Calcineurin-null fibroblast-derived matrices induce
cytoskeletal reorganization.
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Figure 2.4: Calcineurin-null fibroblast-derived matrices induce cytoskeletal reorganization. A.
Confocal images of WT fibroblasts cultured on WT or Cn-/- fibroblast-derived matrix (FDM) and stained
with paxillin (red), phalloidin (green), and DAPI (blue). Aspect ratio was calculated by dividing the
width by the length for each cell. Bar = 50 µm. B. Confocal images of MH6449 PDAC cells cultured on
WT or Cn-/- FDMs and stained with phalloidin (green) and DAPI (blue). Bar = 50 µm. Assay was
performed in triplicate. ***p<0.001, ****p<0.0001. C. Representative live-cell tracking images of
PDACs on WT or Cn-/- FDMs with magnified representative area denoted by dotted yellow box. Each
line is an individual cell’s path over 24 hours. Bar = 200 µm. D. Quantification of mean square
displacement and straightness of cell track. Each data point represents the average value from all cell
tracks in 1 image. Assay was performed in duplicate, values pooled from N=6 images/videos per
replicate. Error bar = standard deviation.
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Loss of calcineurin in fibroblasts promotes EC tube formation
Activated fibroblasts and their associated matrix play a crucial role in angiogenesis,
both by providing structural support and by secreting pro-angiogenic factors. We utilized
a co-culture model of EC tube formation in which primary lung ECs were mixed with WT
or Cn-/- fibroblasts on basement membrane extract (BME), and 2D tube formation was
quantified. Cn-/- fibroblasts supported more robust EC tube formation measured by number
of tube segments and branch points as compared to WT fibroblasts (Figure 2.5A).
Therefore, we examined the secretome of WT and Cn-/- fibroblasts during tube
formation. We generated conditioned media from WT and Cn-/- fibroblasts cultured on
BME and probed for angiogenesis-related proteins. Deletion of CN led to significant
upregulation of multiple cytokines and growth factors, including SDF-1, a chemokine that
has been shown to promote angiogenesis as well as the myofibroblast phenotype in both
cancer and fibrotic disease129–132 (Figure 2.5B). Thus, the differences observed in our in
vitro tubulogenesis assays may be at least partially mediated by differences in angiogenic
secreted factors of CN-null fibroblasts.
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Figure 5: Cn-/- fibroblasts promote angiogenesis.
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fibroblasts that may be pro-tumorigenic. To investigate tumor growth and metastases in
mice with fibroblast specific deletion of calcineurin, we cross-bred calcineurin B floxed
mice with transgenic mice expressing tamoxifen-inducible Cre driven by a fragment of the
type I collagen alpha-1 chain promoter (Col1a1-Cre-ER(T))133,134 to delete CN from the
stroma in vivo. While previous literature suggested that the 2.3kb fragment of the Col1a1
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Figure 2.6: Stromal deletion of calcineurin increases the incidence and size of lung metastases.
A. Confirmation of stromal Cn knockdown in lung fibroblasts from Col1a1-Cre-ER(T);CnBfl/fl mice
by Western blot for CnA. B. qPCR for Col1a1-Cre. Each lane represents lung fibroblasts isolated from
1 mouse. C. Schematic of injection-resection spontaneous metastasis experiments in CnBfl/fl (WT) and
Col1a1-Cre-ER(T);CnBfl/fl (KO) mice. d, day. D. Volume of PDAC flank tumors on the indicated days
prior to resection in the injection-resection experiment. E. Quantification of lung metastases (mets)
per mouse and average size of lung mets. Size of lung mets was normalized to total lung area. N=13
(6 WT, 7 KO) each for LLC and PDAC experiments. F. Representative H&E images from PDAC and
LLC lung metastases with fraction of metastasis-bearing mice indicated. Bar = 500 µm. Each slide
represents all lung lobes from a single mouse. Error bar = standard deviation.

promoter is solely expressed in dermal fibroblasts (along with osteoblasts and
osteoclasts),we demonstrated Cre expression as well as a significant decrease in CN
expression in lung fibroblasts after 1 week of tamoxifen administration (Figure 2.6A).
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To examine both primary tumor growth and metastases, we utilized an injectionresection experimental model of spontaneous lung metastasis using two separate tumor cell
lines: Lewis lung carcinoma and the MH6449 PDAC cell line. Following tamoxifen
injection to delete CN from fibroblasts, subcutaneous tumors were established and allowed
to grow to 400-600 mm3 before resection; 14 days following resection, mice were
sacrificed and lungs analyzed for metastases (Figure 2.6B). There was no significant
difference in primary tumor growth between Cnfl/fl (WT) and Col1a1-Cre;CnD/D mice
(Figure 2.6C). However, there was an increase in the size of LLC lung mets and a trend
towards larger PDAC lung metastases in Col1a1-Cre;CnD/D

mice (Figure 2.6D).

Additionally, 6/6 of stromal Cn D/D vs 4/6 WT mice in the LLC and 4/6 vs 2/6 in the PDAC
model developed visible lung metastases, indicating an increase in the development of lung
metastases upon CN deletion in lung fibroblasts (Figure 2.6E). These data suggest that
stromal deletion of CN specifically increases both the colonization and outgrowth of lung
metastases.
Expression of constitutively active NFAT signaling partially rescues CN deletion
To determine whether restoration of NFAT activation could rescue the phenotype
of Cn-/- fibroblasts and limit fibroblast activation, we transduced Cn-/- fibroblasts with a
constitutively nuclear form of NFATc1 (caNFATc1) (Figure 2.7A) and assayed its effects
on collagen remodeling and migration. Expression of caNFATc1 partially reversed the
increase in collagenase activity of Cn-/- fibroblasts in DQ type I collagen assays as
compared to Cn-/- fibroblasts (Figure 2.7B). However, scratch assays on Cn-/- fibroblasts
with caNFATc1 expression showed similar increased migration and a flattened fibroblast
morphology similar to Cn-/- fibroblasts (Figure 2.7D) and had a nominal effect on fibrillar
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collagen remodeling in fibroblasts cultured on type I collagen gels (Figure 2.7C). These
data suggest that restoration of NFAT signaling leads to a decrease in collagenase activity
by CN-null fibroblasts similar to WT fibroblasts but does not significantly affect fibroblast
migration and fibrillar collagen remodeling.

Figure 2.7: Constitutively active NFAT partially rescues CN deletion. A. P3 Cn-/- fibroblasts
treated with pMX-puro or pMX-caNFATc1 were cultured in 10% FBS containing media overnight
before being stained for NFATc1 localization (red). Each condition was performed in duplicate. Bar =
100 µm. B. DQ collagen was incubated for 24 hours with Cn-/- fibroblasts treated with pMX-puro or
pMX-caNFATc1 on gelatin-coated glass chamber slides. Bar = 100 µm. C. Cn-/- fibroblasts were
plated on thick 1mg/ml collagen gels for 48 hours, and collagen fibrils were imaged using 2P-SHG. 5
images taken per plate. Green = SHG; white = autofluorescent cells. Bar = 100 µm. D. Cn-/- fibroblast
treated with pMX-puro or pMX-caNFATc1 were wounded with a pipet tip, and migration in 10%
serum-containing media was measured. Red dotted lines denote original width of scratch. Bar = 250
µm. N=2-3 technical replicates per experiment, N=1 experimental replicate.

Discussion
In this study, we characterized the effect of CN deletion in fibroblasts in vitro and
in vivo. Our data show that calcineurin deletion in fibroblasts in vitro leads to a number of
functional alterations consistent with an activated, pro-tumorigenic fibroblast phenotype.
This suggests CN may play a crucial role in the maintenance of fibroblast homeostasis or
the “un-activated” state. We demonstrate that Cn-/- fibroblasts exhibited greater migratory
capacity during scratch assays and transwell migration assays; however, they do not invade
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through type I collagen gels to the same extent as WT. Our studies identified a role for CN
in the deposition and remodeling of extracellular matrix, particularly collagen, with Cn-/fibroblasts exhibiting increased collagenase activity and collagen remodeling. CN deletion
leads to an increase in fibrillar collagen in Cn-/- fibroblast-derived matrices and when Cn-/fibroblasts are cultured on type I collagen gels. These differences in matrix direct the
cytoskeletal reorganization of both fibroblasts and tumor cells, and tumor cells exhibit
more linearly directed movement when cultured on Cn-/- matrix. Finally, our in vitro studies
show that CN-null fibroblasts promote endothelial cell tube formation and increase their
production of angiogenesis-related proteins. Fibroblast-specific deletion of CN in vivo
increased the incidence and size of lung metastases in an experimental model of
spontaneous metastasis. Our data suggest that CN deletion leads to an activated fibroblast
phenotype in the absence of activating stimuli, phenocopying cancer-associated, protumorigenic fibroblasts.
We show that CN deletion leads to an increase in fibroblast migratory capacity, but
a decrease in invasion through type I collagen. Given that Cn-/- fibroblasts demonstrated
increased collagenase activity in other assays, it is unlikely that this phenotype is caused
by a decrease in collagen proteolysis. It is possible that the increased collagenase activity
as observed in the DQ collagen assays revealed a greater number of cryptic binding sites
to which the Cn-/- fibroblasts can bind via engagement of their integrins, or that the increase
in fibrillar collagen as observed by SHG imaging of Cn-/- fibroblasts on type I collagen gels
encouraged engagement of integrins with specificity for collagen in its triple helical fibril
structure, such as integrins a1b1 and a2b150. This pro-remodeling phenotype may promote
interactivity with the collagen substratum instead of invasion through it.
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Our work also identifies a role for CN in the secretion and remodeling of
extracellular matrix, specifically in collagen. Cn-/- fibroblasts are capable of both
remodeling and exerting contractile forces on existing collagen substrates as well as
secreting and remodeling new ECM de novo to a greater extent than WT fibroblasts.
However, we observed no difference in gelatinase activity, suggesting that calcineurin
specifically regulates the processing of fibrillar collagen and not its denatured form,
possibly through differential expression of collagenases but not gelatinases. Fibroblastderived matrices generated using Cn-/- fibroblasts have a greater amount of fibrillar
collagen that is more linearly aligned, findings that are consistent with FDMs generated
from cancer-associated fibroblasts compared to normal fibroblasts135. In support of this
hypothesis, WT FDMs generated in the presence of tumor-conditioned media resemble Cn/-

FDMs generated in normal growth media, and Cn-/- FDMs do not undergo further changes

when generated in the presence of tumor-conditioned media.
We then demonstrated that the matrix derived from Cn-/- fibroblasts is sufficient to
direct the cytoskeletal architecture of both WT fibroblasts and PDAC tumor cells, causing
their aspect ratio to increase. The elongation of PDACs on Cn-/- FDMs as measured by cell
aspect ratio may be an indicator that these cells are undergoing epithelial-to-mesenchymal
transition (EMT) at a higher rate than PDACs cultured on WT FDMs. The increased
straightness of tumor cell migration paths on Cn-/- FDMs, as well as the right-skewing of
the mean square displacement distribution of PDACs on Cn-/- FDMs, corresponds to their
increased migration along the more linearly aligned collagen fibrils, a phenomenon that is
frequently observed in tumor growth and invasion in vivo136.
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We propose that the alterations in collagen fiber architecture we observed in vitro
may inform the increase in the incidence and size of metastases in stromal CN-null mice
in an experimental model of spontaneous metastasis. We did not observe gross differences
in collagen fiber morphology or density, or in microvessel density in the PDAC primary
tumors from the injection-resection experiments (data not shown); however, at the time of
resection, these tumors were very large (~500 mm3), well past the size at which the
angiogenic and stromagenic switch occur7,119. It may be that differences in ECM
architecture and angiogenesis at earlier time points may enhance the intravasation of tumor
cells, and analyzing tumors at the time of resection masks any differences that may be more
apparent earlier, despite no difference in the rate of primary tumor growth.
Our work identifies calcineurin as one of the necessary signaling pathways through
which fibroblast homeostasis is regulated, as deletion of calcineurin leads to activation in
the absence of exogenous activating stimuli such as TGF-b. While our work is the first to
identify a role for CN specifically in fibroblast homeostasis, CN deletion has been shown
to disrupt homeostasis in many other cell types and disease models137–140. The current
literature examining the role of CN/NFAT signaling in fibroblast activation, however, is
complex. Evidence exists for both pro- and anti-fibrotic effects of CN/NFAT signaling in
fibroblasts isolated from a variety of tissues106–114. However, it is important to note that
some of this work was conducted using pharmacologic inhibition of CN via CsA; we and
others have shown that CsA has a significant number of calcineurin-independent targets
and effects115,116, and the anti-fibrotic effects of CsA observed in one study were not
recapitulated when tacrolimus, a CN inhibitor with a different mechanism of action, was
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utilized117. Therefore, it is possible that many of the anti-fibrotic effects of CsA
administration that have been previously observed are due to its off-target effects.
We must consider whether the activated phenotype of Cn-/- fibroblasts is dependent
on NFAT signaling, as CN has been shown to dephosphorylate a number of other targets
outside of NFAT93,141. Previous evidence suggests that NFAT is activated in response to
activating stimuli such as mechanical stretching or TGF-b treatment111,142; however,
constitutively active NFAT can instead suppress myofibroblast transdifferentiation143. One
possible NFAT target that may be at least partially responsible for the phenotype we
observed is SDF-1/CXCL12, a pro-fibrotic and pro-angiogenic chemokine that was
upregulated in Cn-/- fibroblasts in our angiogenic secretome array as well as in
cytokine/chemokine secretome arrays generated from fibroblasts cultured on both type I
collagen gels and fibronectin-coated hydrogels (data not shown). Some evidence exists for
the negative regulation of SDF-1 by NFAT in osteoblasts144 and cytotrophoblast cells145.
Thus, one potential mechanism by which calcineurin deletion leads to a pro-tumorigenic
phenotype in fibroblasts may be via this increase in autocrine SDF-1 expression.
Collectively, our data demonstrate a role for calcineurin signaling in fibroblast
homeostasis by showing that calcineurin deletion leads to a pro-tumorigenic, activated
phenotype in primary lung fibroblasts, and that stromal deletion of CN in vivo leads to an
increase in the incidence and size of lung metastases. Though the increased incidence of
tumors in transplant patients receiving calcineurin inhibitors has often been attributed to
the desired immune suppressive effects of these drugs, our work demonstrates that the
effects of calcineurin inhibition on the stroma may also a play a part in this phenomenon.
Further elucidation of the specific transcriptional targets of NFAT in lung fibroblasts may
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identify specific signaling cascades through which this homeostasis is maintained as well
as potential pathways to pharmacologically target the stroma.
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CHAPTER 3: CALCINEURIN-NULL FIBROBLASTS DO NOT RESPOND TO
TGF-b STIMULATION IN VITRO.

Introduction
We have shown in Chapter 2 that deletion of calcineurin in primary lung
fibroblasts leads to an activated, pro-tumorigenic phenotype in the absence of exogenous
activating stimuli. Next, we wished to determine how Cn-/- fibroblasts would respond when
activating stimuli were added. Previously, we showed that the content and alignment of
WT fibroblast derived matrices are significantly altered upon the addition of tumor
conditioned media, whereas Cn-/- FDMs are not. This suggests that despite their baseline
activation, Cn-/- fibroblasts may be unable to respond to certain activating stimuli to the
same extent as WT. TGF-b1 is one of the main cytokines responsible for fibroblast
activation in wound healing, fibrotic disease, and cancer; thus, we elected to specifically
investigate the role of CN signaling in the functional response to TGF-b stimulation in
fibroblasts.
The TGF-b superfamily of growth factors consists of a large group of proteins that
are similar in their dimeric protein structure, often featuring disulfide bonding between the
two monomers146. They can be divided into several subgroups: the transforming growth
factors (TGF), bone morphogenic proteins (BMP), activins and inhibins, growth
differentiation factors (GDF), and other factors such as Müllerian inhibiting substance
(MIS). TGF family members are only expressed in vertebrates and play a significant role
in normal development. Additionally, dysregulation of TGF signaling is implicated in a
variety of disease states146: many tumor cells secrete increased levels of TGF-b1, leading
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to widespread inflammatory and pro-fibrotic changes, and TGF-b1 is often implicated as
one of the major inflammatory cytokines responsible for fibrotic disease147.
Given its important role in many developmental and physiologic processes, TGF
signaling is a highly regulated and controlled process. TGF-b is initially secreted in a latent,
inactive form; an N-terminal latency-associated protein (LAP) is disulfide bonded to the
active C-terminal TGF domain, and this bond must be disrupted in order for active TGF-b
to be released148. Active TGF-b binds the TGF-b receptor, a heterodimer consisting of one
type I and one type II receptor; these heterodimers themselves dimerize, forming an active
intracellular kinase complex147. The canonical TGF-b signaling pathway following
engagement and dimerization of the TGF-b receptor occurs when the dimerized TGF-b
receptor phosphorylates regulatory Smad (R-Smad) proteins such as Smad2 and Smad3.
These R-Smads form heterodimers with Smad4, and this heterodimer translocates to the
nucleus and regulates the expression of a wide variety of genes. Control of TGF-b signaling
is mediated by a variety of endogenous inhibitory factors. The expression of inhibitory
Smads (I-Smads) is stimulated by TGF-b signaling, thus forming a negative feedback loop.
The effects of TGF stimulation are often concentration-dependent, with opposing effects
on cellular function and gene expression at low versus high concentrations of TGF149–151.
In many cell types, such as podocytes, TGF-b signaling is pro-proliferative at low
concentrations and becomes pro-apoptotic above a critical threshold concentration, often
in a Smad3-dependent manner152.
TGF-b signaling also varies significantly based on cellular context, as evidenced
by the many often contradictory roles TGF-b plays in different cell types and disease
settings153. Specifically, in fibroblasts, TGF-b1 signaling has been associated with
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differentiation into the myofibroblast phenotype in wound healing, fibrosis, and cancer.
TGF-b stimulation of fibroblasts leads to the upregulation of a number of pro-fibrotic
genes, including ECM proteins such as the a-1 chain of type I collagen (COL1A1) and the
EDA variant of fibronectin (EDA-FN), matrix metalloproteinases (MMPs), and other
collagen remodeling enzymes such as lysyl oxidase (LOX). It also directly regulates the
expression of the myofibroblast marker aSMA and can lead to an increase in contractility
in collagen contraction assays.
Previous studies suggest that calcineurin may play an important role in the response
to TGF-b in fibroblasts. First, TGF-b is known to lead to calcium influx and calcineurin
activity in many cell types, including renal fibroblasts142. Davis et al. then demonstrated
that the expression of the calcium channel TRPC6 independently stimulate myofibroblast
differentiation in a manner very similar to TGF-b treatment; further, deletion of TRPC6
rendered cardiac and dermal fibroblasts unable to differentiate into myofibroblasts in
response to TGF-b, a phenotype that could be replicated. Notably, they identified that
TRPC6 expression was induced by TGF-b through non-canonical signaling via p38 and
SRF66. These findings demonstrating direct effects of TGF-b on calcium influx suggest
that TGF-b signaling results in activation of calcineurin. Finally, there is also some
evidence that CN and TGF-b signaling pathways can affect one another; in T cells, it has
been shown that NFAT may act as a co-transcription factor with Smad2 and Smad3 to
promote the expression of specific genes154,155.
In summary, fibroblast activation in both cancer and fibrotic disease is often
mediated by TGF-b, and calcineurin may at least partially regulate the fibroblast response
to TGF-b stimulation. Therefore, we hypothesized that calcineurin deletion in fibroblasts
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would abrogate their ability to respond functionally to TGF-b stimulation. Thus, we sought
to examine the functional response of WT and Cn-/- lung fibroblasts to TGF-b treatment in
vitro using many of the functional assays described in Chapter 2.

Results
Calcineurin deletion attenuates phenotypic changes in fibroblasts on collagen gels in
response to TGF-b
To determine the effects of calcineurin deletion on TGF-b-induced activation,
fibroblasts were grown on soft 1 mg/ml type I collagen gels and treated with and without
2ng/ml TGF-b + 50 µg/ml ascorbic acid. Ascorbic acid was added to TGF-b treatment, as
we have previously shown that the addition of ascorbate to TGF-b treatment can amplify
FAP expression60. When WT fibroblasts are treated with TGF-b, they undergo a dramatic
change in phenotype: the cells form large, globular clumps with cytoplasmic processes
extending radially from them. Viability dye analysis reveals that these clumps of cells
consist of a largely necrotic center surrounded by a surface of viable cells (data not shown).
Notably, these TGF-b-induced phenotypic changes occurred to a much lesser extent in Cn/-

fibroblasts (Figure 3.1). There was no difference in phenotype when WT fibroblasts were

treated with AdCre, suggesting that this effect is not due to off-target effects of either
adenovirus or Cre. Treating with TGF-b alone in the absence of ascorbic acid gave nearly
identical results; thus, we performed the rest of our assays using TGF-b treatment alone in
order to specifically isolate the role of CN in TGF-b-induced activation.
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Figure 3.1: Phase-contrast imaging of fibroblasts cultured on soft type I collagen gels in the
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phase contrast images were taken at 72h. Scale bar = ~500 um.
4x phase contrast images were taken at 72h. Scale bar = ~500 um.

Calcineurin deletion alters TGF-b-stimulated changes in cytokine secretome
One crucial function of activated fibroblasts is their ability to secrete a variety of
cytokines, chemokines, and growth factors that act in both autocrine and paracrine
manners. It has previously been established that TGF-b treatment leads to alterations in the
cytokine secretome in WT fibroblasts. Thus, we sought to determine which, if any, of these
TGF-b-mediated changes in cytokine secretion might require CN signaling. Conditioned
media collected from WT and Cn-/- fibroblasts cultured on soft type I collagen gels was
analyzed for the expression of 40 cytokines using an antibody array (Figure 3.2A). We
elected to focus on those specific cytokines whose secretion was differentially regulated
(either increased or decreased) in WT fibroblasts upon TGF-b treatment: IL-6, IL-7, MIP1a, MIP-1b, and M-CSF (Figure 3.2B). Of these cytokines, MIP-1a, MIP-1b, and M-CSF
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were expressed at higher levels at baseline in Cn-/- fibroblasts. TGF-b treatment either
increased or decreased levels of IL-6, MIP-1a, and MIP-1b in Cn-/- fibroblasts in a similar
manner to WT. However, IL-7 and M-CSF levels were unaffected in Cn-/- fibroblasts upon
TGF-b treatment, whereas they decreased in WT TGF-treated fibroblasts. Additionally,
while TGF-b treatment did not alter TIMP-1 expression in WT fibroblasts, levels of TIMP1 decreased significantly in Cn-/- fibroblasts upon TGF-b stimulation. Taken together, this
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suggests that TGF-b-mediated regulation of IL-7 and M-CSF secretion are dependent on
calcineurin signaling, and that CN may regulate TIMP-1 levels in the presence of TGF-b.
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TGF-b stimulation does not affect collagen contraction by calcineurin-null fibroblasts
We showed that calcineurin-null fibroblasts exhibit greater collagen remodeling
and contraction when embedded in free-floating collagen gels; in these assays, we also
treated free-floating collagen gels
with TGF-b. As expected, when WT fibroblasts are
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Calcineurin-null fibroblast migration is paradoxically inhibited by TGF-b in in vitro
wound healing assays
We previously demonstrated that Cn-/- fibroblasts exhibit greater wound closure in
in vitro scratch wound healing assays compared to WT. We have previously shown that
TGF-b activation is crucial in inducing fibroblast migration in scratch assays156, so we also
assessed wound closure of WT vs Cn-/- fibroblasts in the presence and absence of TGF-b.
Phase contrast imaging revealed that TGF-b treatment caused WT fibroblasts to extend
more cytoplasmic processes and orient themselves parallel to the scratch wound (Figure
3.4A). However, TGF-b treatment did not significantly alter fibroblast orientation or
morphology in Cn-/- fibroblasts, and fibroblast migration across the scratch wound
appeared to be impaired in the presence of TGF. While TGF-b treatment did not
significantly affect the rate of wound closure in WT fibroblasts as measured by decrease
in wound area over time, live cell imaging showed significant differences in fibroblast
motility, with greater fibroblast movement parallel to the wounded area and more
individual fibroblasts migrating along the scratch wound. Conversely, there was little
difference in morphology or motility of wounded Cn-/- fibroblast monolayers in the
presence of TGF-b; in fact, wound closure rates were slower in Cn-/- fibroblasts when
treated with TGF-b (Figure 3.4B). These findings demonstrate that unlike in WT
fibroblasts, Cn-/- fibroblast motility may actually be hindered by the addition of TGF-b to
scratch wound assays.
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Previous studies from our lab have shown that scratch wounding of WT cell
monolayers leads to an increase in both total TGF-b secretion as well as latent TGF-b
activation in a CD44-dependent manner156. Thus, we compared the amount of TGF-b in
unwounded vs. wounded cell layers in WT and Cn-/- fibroblasts to determine whether the
increased migration observed in Cn-/- fibroblasts is mediated by TGF-b secretion and/or
activation. In order to better assess and amplify any differences in the activation of latent
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TGF-b, we added 30 ng/ml latent TGF-b1 at the time of wounding to all samples. Upon
scratch wounding, the concentration of total TGF-b in the culture media increased in WT
but not Cn-/- fibroblasts (Figure 3.5, left). However, while there was a trend toward
increased levels of active TGF-b in wounded WT fibroblast layers, there were no such
differences when Cn-/- fibroblast layers were wounded (Figure 3.5, right). Therefore, Cn-/fibroblasts are unable to increase levels of either total or active TGF-b in response to
scratch wounding.
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Smad phosphorylation in response to TGF-b is intact in calcineurin-null fibroblasts
Given the lack of functional response of Cn-/- fibroblasts to TGF-b stimulation, we
wished to determine where specifically in the TGF-b signaling cascade signal transduction
was impaired. Fibroblasts cultured on plastic were treated with 2 ng/ml TGF-b for 1 or 12h
and analyzed via Western blot for Smad2 phosphorylation. In both WT and Cn-/-

55

fibroblasts, Smad2 phosphorylation was induced following both 1 and 12 hours of TGF-b
treatment, suggesting that calcineurin is not required for TGF-b-induced Smad2
phosphorylation (Figure 3.6).
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Discussion
These data suggest that while calcineurin-null fibroblasts are activated at baseline,
they are unable to respond functionally in response to TGF-b treatment. We demonstrate
that CN is required for several phenotypic and functional changes induced by TGF-b in
WT fibroblasts. The significance of the cell clumping phenomenon when WT fibroblasts
are cultured on collagen gels and treated with TGF is still somewhat unclear; there is
significant collagen remodeling as shown by both phase contrast and 2P-SHG imaging,
suggesting that this alteration in morphology is directly related to fibrillar collagen reorientation. The clumping of cells could represent an increase in motility and/or
proliferation. Given that proliferation assays have shown that treatment with TGF-b
impairs fibroblast proliferation, it is more likely that the clumping observed is a result of
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alterations in fibroblast motility and aggregation. Regardless of their functional
significance, these changes do not occur in Cn-/- fibroblasts.
Similar to the angiogenesis array performed on WT and Cn-/- fibroblasts cultured
on BME, secretome array analysis of cells cultured on soft type I collagen gels revealed
global changes in the cytokine secretome of Cn-/- fibroblasts at baseline compared to WT.
Our findings in WT fibroblasts are consistent with previous literature evidence regarding
the effects of TGF-b on the fibroblast secretome; TGF-b has been shown to upregulate IL6 in human lung fibroblasts157, and there is evidence in macrophages that it can
downregulate MIP-1a expression158. Further, the decrease in IL-7 and increase in M-CSF
secretion induced in WT fibroblasts by TGF-b treatment may be dependent on CN
signaling, as these changes were effectively abrogated in Cn-/- fibroblasts. Just as
importantly, calcineurin does not appear to be required for TGF-b-mediated stimulation of
IL-6, a pro-inflammatory and pro-fibrotic cytokine that has been implicated in the
pathogenesis of pulmonary fibrosis159.
Finally, we demonstrated that TGF-b treatment increased contractility in WT
fibroblasts in collagen contraction assays, consistent with data from our and others’ prior
studies. However, TGF-b did not affect contractility and/or remodeling of Cn-/- fibroblasts
on type I collagen. Taken together, these three experiments show that CN deletion in
fibroblasts renders them unable to respond to TGF-b stimulation when cultured on soft
type I collagen.
Further, we show that the increase in wound closure and alterations in cell
morphology and orientation in Cn-/- fibroblasts compared to WT are not due to differences
in TGF-b signaling. Since we had previously showed that scratch wounding led to
57

increased secretion and activation of TGF-b, and that Cn-/- fibroblast motility and
morphology in scratch assays resembled WT TGF-treated fibroblasts, we hypothesized that
Cn-/- fibroblasts might secrete or activate more TGF-b in scratch assays. However, levels
of TGF in wounded Cn-/- fibroblast-conditioned media did not differ from WT, and
wounding Cn-/- fibroblast monolayers did not lead to an increase in secretion or activation
of TGF. Of note, in our assays, there was not a significant difference in TGF-b activation
upon scratch wounding in WT fibroblasts, whereas previous studies have observed an
increase in TGF-b activation in response to wounding. However, it is likely that ELISAbased assay we utilized was less sensitive to small changes in active TGF-b compared to
the reporter assay that was previously used.
Finally, we show that Cn-/- fibroblasts are capable of phosphorylating Smad2 in
response to TGF-b treatment. This suggests that the block in TGF-b signaling in Cn-/fibroblasts occurs either downstream or independently of Smad2 phosphorylation. These
findings are consistent with previous literature, which has shown that calcineurin activation
occurs via non-canonical TGF-b signaling. However, our results are complicated by the
fact that these fibroblasts were cultured on tissue culture plastic, a substrate thousands of
times stiffer than physiologic conditions. Due to this increase in substratum stiffness, the
fibroblasts were already in an activated state and thus had a significant baseline amount of
TGF-b secretion and Smad phosphorylation, possibly masking any further increases in
response to TGF-b treatment. Future studies should investigate the mechanisms of Smad
phosphorylation and other downstream aspects of TGF signaling on softer substrates such
as collagen gels or polyacrylamide hydrogels as well as on fibroblast-derived matrices.
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There are two main possibilities as to why Cn-/- fibroblasts may be unable to
respond to TGF-b stimulus. First, calcineurin may be required for the signaling
mechanisms downstream of TGF-b engagement with its receptor. The introduction to this
chapter outlines specific literature evidence that TGF-b directly leads to calcium influx.
Another possibility is that activation-related transcriptional programs are already active in
Cn-/- fibroblasts due to dysregulation of fibroblast homeostasis. Thus, further treatment
with an activating stimulus such as TGF-b would have no effect since these pathways have
already been activated. At the same time, given the heterogeneity of activated fibroblasts,
it is unlikely that a single transcriptional program is responsible for the entirety of the
activated fibroblast phenotype. It is important to note, though, that these hypotheses are
not mutually exclusive, and the lack of response to activating stimulus may be due to both
decreased TGF-b-mediated calcium influx and increased transduction of activation-related
signaling pathways in Cn-/- fibroblasts.
These experiments merely represent preliminary investigations into the role of CN
signaling in the TGF-b response, and much remains to be investigated. First, it is crucial
to determine specifically which parts of the TGF-b signaling pathway in fibroblasts are
affected by calcineurin signaling. One way of achieving this is to further define which
functional and transcriptional aspects of TGF-b-mediated activation require calcineurin
signaling. Further understanding of alterations in NFAT targets upon TGF-b treatment
would help determine how specifically calcineurin deletion leads to a functional inability
to respond to TGF stimulation.
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CHAPTER 4: THE EFFECTS OF STROMAL CALCINEURIN DELETION IN
VARIOUS IN VIVO MODELS.

Introduction
The in vivo data presented in Chapter 2 suggest that the phenotypic changes
observed in lung fibroblasts in vitro are relevant to in vivo models of metastasis, as the protumorigenic changes observed in functional studies correlate with an increase in metastatic
outgrowth in mouse models. However, it is also important to more broadly characterize the
role of calcineurin signaling in fibroblasts in vivo, as fibroblasts play key roles in a large
number of physiologic and pathologic processes. While few studies have been performed
examining the role of CN in cancer-associated stroma in vivo, as discussed in Chapter 1,
prior data suggest that stromal CN plays a role in a variety of other in vivo models,
including fibrosis, wound healing, and cardiac remodeling. This chapter describes our
efforts to define the effects of stromal CN deletion in several in vivo models, encompassing
both physiologic and disease processes.

Results
Calcineurin is required for stiffness-dependent regulation of FAP but not aSMA expression
To assess how fibroblast activation is affected when CN is deleted from fibroblasts
in vivo, we investigated fibroblast activation and activation marker expression in vitro on
a substratum that mimicked in vivo conditions. We utilized a tunable polyacrylamide
hydrogel system in order to replicate the stiffness of soft/less fibrotic (2 kPa) and stiff/more
fibrotic (20-25 kPa) lung tissue in vitro160. When Cn-/- fibroblasts are grown on 2 kPa
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fibronectin-coated hydrogels, they spread to a greater extent (Figure 4.1A). While the
average cell size was the same in both groups, the distribution of cellular size of Cn-/fibroblasts was shifted further to the right and had more weight in the right tail of the
distribution (as measured by kurtosis) compared to WT fibroblasts, implying that Cn-/fibroblasts had a higher proportion of large, spread cells when cultured on soft hydrogels
(Figure 4.1B). Unlike on soft substrates, there were no noticeable differences in
morphology between WT and Cn-/- fibroblasts when cultured on 25 kPa hydrogels. We
have previously observed that 2 kPa fibronectin-coated hydrogels select for a FAPhi
population in WT fibroblasts, whereas stiffer substrates shift the fibroblast phenotype to
one that is aSMAhi and more myofibroblastic60. FAP and aSMA expression by WT and
Cn-/- fibroblasts on hydrogels was assessed by flow cytometry and revealed that Cn-/fibroblasts are unable to upregulate FAP on soft substrates, while aSMA expression is
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comparable to that of WT fibroblasts. These data suggest that CN deletion alters both
cytoskeletal morphology and FAP expression of fibroblasts on soft, but not stiff, substrates.

Loss of CN in fibroblasts does not affect tumor cell colonization of the lung
While the injection-resection model of metastasis we utilized is a physiologically
relevant model of spontaneous metastasis, it cannot specifically identify which aspect of
metastasis is altered by stromal calcineurin deletion, such as extravasation, intravasation,
or colonization. We investigated the role of stromal calcineurin deletion in tumor cell
migration, lung colonization, and micrometastatic formation using intravenous tumor cell
injection. We injected WT and stromal CN-null mice (Col1a1-Cre) intravenously into the
lateral tail vein with SKPY42.1 cells, a YFP-expressing clonal cell line isolated from a
model of undifferentiated pleomorphic sarcoma featuring oncogenic Kras and p53
deletion161. We observed no significant difference in lung colonization between the WT
and Col1a1-Cre mice as measured by H&E staining at multiple time points (Figure 4.2A).
Flow cytometry of murine lungs for YFP+ tumor cells revealed an increase in cell number
at 4 days in Col1a1-Cre mice following tumor cell injection; however, this difference was
highly variable and not statistically significant (Figure 4.2B). Quantification of YFP+
tumor cells in the lung at later timepoints by flow cytometry also did not reveal any
differences between WT and stromal CN-null mice. Taken together, these data show that
colonization of the lung by sarcoma cells is not affected by stromal CN deletion.
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Stromal calcineurin deletion alters collagen content in the lung at baseline
Prior studies suggest that CN signaling may modulate fibrosis, and chronic
calcineurin inhibition is associated with fibrotic disease. Therefore, we examined the role
of stromal CN deletion in a bleomycin-induced model of lung fibrosis using Masson’s
trichrome staining of lung sections and quantification of total collagen (blue) signal.
Col1a1-Cre mice in the absence of bleomycin demonstrated a trend toward higher amounts
of collagen in the lung compared to WT; however, there was no difference in collagen
content between WT and Col1a1-Cre mice treated with bleomycin (Figure 4.3). chis
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suggests that stromal CN deletion may lead to baseline differences in collagen content in
the lung but does not affect the fibrotic response to bleomycin in this model.
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Stromal calcineurin deletion does not alter kinetics of dermal wound closure
Previous literature has identified a potential role for calcineurin signaling in dermal
wound healing66; therefore, we elected to study the kinetics of wound healing in mice with
stromal CN deletion using bilateral punch biopsies on the dorsal skin. We observed no
difference in wound closure kinetics between CnBfl/fl and Col1a1-Cre;CnBfl/fl mice (Figure
4.4), suggesting that stromal CN is not required for timely wound closure.
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Discussion
We demonstrated that stromal CN deletion using the Col1a1-Cre-ER(T);CnBfl/fl
mouse did not affect outcomes in models of lung tumor cell colonization, lung fibrosis, and
dermal wound healing. However, study of fibroblast morphology and activation marker
expression using a physiologically relevant 3D culture demonstrated that stiffnessdependent modulation of FAP, but not aSMA, on fibronectin-coated substrata may require
calcineurin signaling.
Our data suggest that deletion of calcineurin in lung fibroblasts alters cell
morphology when cultured on fibronectin-coated hydrogels tuned to physiologically
relevant stiffness. Consistent with our previous studies, we showed that on soft (2 kPa)
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fibronectin-coated hydrogels, WT fibroblasts expressed FAP at higher levels compared to
when they are cultured on stiff (20-25 kPa) fibronectin-coated hydrogels. In comparison,
Cn-/- fibroblasts did not upregulate their expression of FAP when they are cultured on soft
hydrogels. Calcineurin deletion did not affect stiffness-dependent regulation of aSMA
expression. Similarly, Cn-/- fibroblasts exhibited increased cell spreading compared to WT
on soft, but not stiff, hydrogels, suggesting that CN deletion may specifically affect the
FAP+ population of fibroblasts. These results are not consistent with the literature findings
mentioned in Chapter 1, which suggest that calcineurin is required for the aSMA+
myofibroblast phenotype. However, it is likely that the CN-mediated regulation of
activation marker expression is substratum-dependent; for example, preliminary data
suggests that FAP is upregulated in Cn-/- fibroblasts compared to WT when they are
cultured on type I collagen gels (data not shown). At the same time, analysis of the
promoter regions of FAP and aSMA show that FAP contains multiple consensus binding
sequences for NFAT, whereas aSMA does not (see Conclusions and Future Directions).
It may be that NFAT directly regulates FAP expression but not aSMA, but that CN/NFAT
modulates the myofibroblast phenotype and aSMA expression indirectly by affecting
transduction through other signaling pathways.
One possibility that might explain these negative results in vivo is that calcineurin
deletion in lung fibroblasts at the protein level was only partial (~60% deletion) despite
observing high levels of Col1a1-Cre expression via qPCR. Residual CN-expressing
fibroblasts may have been sufficient to mask subtle differences in disease progression in
these models. There are several possibilities as to why CN was not completely deleted from
fibroblasts in vivo. First, Col1a1-Cre expression may vary significantly in various
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subpopulations of lung fibroblasts. Expression of the 2.3kb fragment of the Col1a1
promoter had not previously been assessed in adult lung fibroblasts, and we demonstrated
its expression via qPCR. However, while the complete Col1a1 promoter is expressed in all
fibroblasts, the 2.3kb fragment may only be expressed in certain fibroblast subpopulations,
leading to incomplete deletion of CN in all lung fibroblasts. Second, despite continually
administering tamoxifen, stromal precursors that do not yet express Cre via the Col1a1
promoter may still be actively recruited from the bone marrow and escape deletion in this
manner. A third possibility is that the process of isolation via selection for adherent
fibroblasts artificially selects for those fibroblasts that did not undergo CN deletion due to
differences in adhesion and/or proliferation of Cn-/- fibroblasts.
However, it may be that stromal CN deletion is sufficient to cause phenotypic
differences in these lung fibroblasts, but that we did not observe differences in these disease
models for other reasons. First, while intravenous tumor cell injections are a commonly
utilized experimental model of tumor cell colonization in the lung, this approach is not the
most physiologically relevant or accurate model of lung metastasis. Primary tumors are
known to secrete circulating factors, including cytokines and exosomes, that prime the lung
for metastasis. In the absence of primary tumor conditioning, there may be no significant
differences in lung colonization at baseline. Additionally, our intravenous tumor
colonization assays utilized sarcoma tumor cells; unlike the Lewis lung carcinoma and
PDAC cells used in our injection-resection assays, these tumor cells are of mesenchymal
origin. Because of this, their interactions with the microenvironment are likely different
compared to epithelial tumor cell lines. Indeed, the majority of studies examining the role
of fibroblasts in cancer have been performed in epithelial tumor cell lines, and the role of
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activated fibroblasts in mesenchymal tumors is less well defined. Therefore, it may be that
SKPY42.1 colonization and outgrowth are unaffected by stromal CN deletion, whereas
LLC or PDAC would demonstrate significant differences in one or both of these metrics.
Future studies will specifically examine the effects of stromal CN deletion on PDAC
colonization and outgrowth.
Next, the bleomycin lung fibrosis assays are complicated by the fact that the lung
fibrosis we observed was not statistically significant in WT mice. That having been said,
the increase in collagen content in the lungs of untreated Col1a1-Cre mice is consistent
with our in vitro findings that Cn-/- fibroblasts are more activated in the absence of
activating stimuli compared to WT. By increasing the bleomycin dosage, number of doses,
or by administering the bleomycin intratracheally instead of intraperitoneally, the amount
of fibrosis induced would be significantly greater, possibly amplifying any differences in
lung fibrosis between WT and stromal CN-null mice. Even if stromal CN deletion is shown
to increase lung fibrosis, this difference may instead be due to the increase in collagen
content seen at baseline; therefore, a more relevant metric might be to compare the increase
in collagen content between untreated and bleomycin-treated conditions. This would
specifically assess whether stromal CN leads to more or less robust induction of fibrosis
upon exposure to bleomycin.
Finally, in the case of dermal wound healing, wound closure kinetics may not be
the most relevant measurement by which to analyze the mechanism of wound healing in
stromal CN knockout mice. Our lab has previously shown that CD44 deletion in mice does
not affect the time it takes for a dermal wound to close; however, the kinetics of fibroblast
activation and ECM reorganization in the healing wound are significantly altered162. Thus,
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future studies should focus on the fibroblast activation and ECM dynamics in the
developing dermal wound in order to determine whether or not stromal CN deletion affects
these particular readouts.
Taken together, these results highlight the importance of selecting physiologically
and experimentally relevant biological assays. While the negative results seen may
represent the fact that stromal CN deletion indeed has no effect on lung colonization,
bleomycin-induced fibrosis, or dermal wound healing, it is important to further optimize
experimental conditions to ensure maximal likelihood that any true differences are
detected. Additionally, the functional assays in vitro identified a specific role for CN in
maintenance of the quiescent, homeostatic state. It may be of greater interest to further
assess these mice in non-disease-stimulated settings and profile their tissues at baseline, as
stromal CN may lead to greater amounts of activation and fibrosis in the absence of disease
compared to WT.
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CONCLUSIONS AND FUTURE DIRECTIONS

Taken together, my work demonstrates that calcineurin plays an important role in
fibroblast homeostasis and activation, the response to TGF-b stimulation, and tumor
growth in vitro and in vivo. I showed that calcineurin deletion leads to a baseline phenotype
consistent with an activated, pro-tumorigenic, CAF-like state in lung fibroblasts, and that
this phenotype promotes metastatic outgrowth in vivo. Then, I outlined preliminary work
that shows that calcineurin is required for fibroblasts to functionally respond to TGF-b
stimulation. Finally, I further examined the role of stromal CN deletion in a number of in
vivo assays. This work has identified an important regulator of fibroblast homeostasis that
may also mediate their ability to respond to activating stimuli such as TGF-b. Future
studies should seek to further define the disruption of homeostasis by CN deletion, delve
into the specific transcriptional mechanisms behind the functional phenotype of CN-null
fibroblasts, and investigate other aspects of the effects of stromal CN deletion in vivo.

Figure 5.1: Schematic describing the role of calcineurin in maintaining fibroblast homeostasis.
Illustration of fibroblasts adapted from Kanasaki et al, Front. Endo 2013.
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Calcineurin regulates functional fibroblast homeostasis
Collectively, my data demonstrate that calcineurin deletion from fibroblasts leads
to a phenotype that is overall consistent with greater activation “at baseline.” First, it is
important to recognize that the “baseline” at which fibroblasts are studied is still far from
the quiescent conditions that would be observed in vivo. Tissue culture plastic has an elastic
modulus in the gigapascal range, several orders of magnitude stiffer than the majority of
tissues in the body; therefore, when fibroblasts are cultured on traditional tissue culture
dishes, they are activated by this significant increase in mechanical stiffness. While my
experiments were often performed on soft (<1kPa) type I collagen gels or tuned
polyacrylamide hydrogels, all primary fibroblasts were still isolated by selecting for
adherent cells on tissue culture plastic, and they were cultured on either uncoated or gelatincoated tissue culture dishes prior to use in experiments. We and others have shown
significant plasticity of the fibroblast phenotype, with fibroblasts able to downregulate
aSMA expression when they are moved from a stiff to a soft substratum60,85. While
passaging cells onto a softer substrate may partially “deactivate” these primary fibroblasts,
there is evidence that activation of fibroblasts can induce long-term epigenetic
modifications57, and the effects of even transient culture on substrata of supraphysiologic
mechanical stiffness cannot be discounted.
My data identify a role for CN signaling in several functional readouts of fibroblast
activation, especially those related to the deposition and remodeling of extracellular matrix.
The functional changes upon deletion of CN in fibroblasts lead to an activated, protumorigenic, more CAF-like phenotype. Deletion of CN leads to the formation of
fibroblast-derived matrices that have a greater amount of, more linearized, and parallel-
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oriented collagen fibers; the architecture of Cn-/- FDMs is consistent with a TACS-2 to
TACS-3 collagen signal, whereas WT FDMs more closely resemble TACS-1. The
differences between WT and Cn-/- FDMs parallel the changes in collagen architecture
during tumor progression. When PDAC tumor cells are cultured on Cn-/- FDMs, they
become more migratory and adopt a more elongated morphology, two behaviors that are
often consistent with greater tumor cell invasion. Whether the changes in morphology and
motility observed in PDAC cells are associated with greater epithelial-mesenchymal
transition (EMT) on Cn-/- FDMs compared to WT FDMs is an interesting question that
should be addressed in the future.
Another important, still unanswered question is whether the phenotype of CN-null
fibroblasts we have observed relies on NFAT signaling, and if so, which activationassociated genes are regulated by NFAT. While there is not yet evidence of calcineurinmediated regulation of the expression of many activation-associated genes, we have shown
that many of these genes contain at least one NFAT binding site, suggesting that NFAT is
at least capable of either activating or repressing their transcription. Using ConTra V3, an
online resource that allows for the identification and visualization of primer binding sites
in genes from a variety of organisms163, we identified a number of activation-associated
murine genes that contained at least one NFAT binding consensus sequence, including
fibroblast activation protein (FAP) and several collagen genes, suggesting that NFAT
signaling may specifically be able to modulate the phenotypes we observed (data not
shown). It is important to note that because NFAT requires a transcriptional co-factor for
optimal DNA binding, a gene does not necessarily need to contain an NFAT consensus
sequence in order for it to be regulated by NFAT. Because NFAT has weak DNA-binding
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capabilities that often require co-activation by another transcription factor, the presence of
an NFAT binding site in a gene’s promoter is not sufficient evidence that it is regulated by
NFAT in vivo.
More recently, the general philosophy surrounding activated fibroblasts has shifted
to define a cell state of “activation” rather than the cell type of “activated fibroblast57.”
Similarly, quiescence is now thought of as a state requiring active maintenance as opposed
to a default cellular state. My data suggest that calcineurin is required to maintain the
quiescent state, restrain the activated state, or, possibly, both. One complication with many
of the studies that claim to “deprogram” activated fibroblasts into a quiescent state is that
they often introduce genetic alterations or drug treatment prior to exposure to the activating
stimulus, thus instead showing that these perturbations block activation. Thus, it will be
critical to assess the role of calcineurin both in maintaining homeostasis in quiescent
fibroblasts as well as potentially deprogramming or “deactivating” activated fibroblasts.
While my work is the first to identify a role for CN specifically in fibroblast
homeostasis, CN deletion or inhibition has been shown to disrupt homeostasis in many
other cell types and disease models. One of the main methods through which calcineurin
inhibitors prevent transplant rejection is by promoting the recruitment and activity of
myeloid-derived suppressor cells (MDSCs); further, evidence suggests that CN/NFAT may
control homeostasis of many innate immune cell populations137,138. Additionally, inhibition
of calcineurin has been shown to induce tumor-promoting effects in keratinocytes, which
may partially account for the increase in cutaneous squamous cell carcinomas seen in
patients treated long-term with calcineurin inhibitors139. In neurons, calcineurin modulates
retinoic acid synthesis, and prolonged calcineurin inhibition leads to an increase in
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excitatory neuron activity and a loss of homeostatic synaptic plasticity140. Therefore, there
is a precedent for CN playing a role in homeostasis.
Further, despite their activation at baseline, my data show that Cn-/- fibroblasts are
unable to respond to specific activating stimuli. Unlike WT fibroblasts, they do not
significantly remodel their secreted matrix when treated with tumor cell-conditioned media
compared to control media. Tumor-conditioned media consists of a large number of
different growth facts, cytokines, chemokines, and exosomes secreted by tumor cells, and
it is unclear which of these factors are responsible for the remodeling of FDMs observed
in WT fibroblasts, or which of these factors requires CN for their secretion. Given that my
data identified an impaired functional response to TGF-b in Cn-/- fibroblasts, and because
many tumors secrete TGF-b, it may be that the inability of Cn-/- fibroblasts to respond to
tumor-conditioned media is at least partially mediated by TGF-b. In order to test this
hypothesis, fibroblast-derived matrices could be generated in the presence and absence of
TGF-b to determine whether TGF-b treatment alone is sufficient to induce these changes
in FDM architecture in WT fibroblasts. TGF-b neutralizing antibodies could also be added
to tumor-conditioned media to determine whether TGF-b signaling is required for tumor
cell-induced changes in WT FDMs.

Future directions to further characterize the role of CN in fibroblast homeostasis
In order to complement the current genetic deletion studies, pharmacologic
inhibition of CN should be performed to determine whether inhibition of phosphatase
activity of CN is sufficient to recapitulate the phenotype observed in CN-null fibroblasts.
Additionally, specifically inhibiting NFAT would help to determine whether the activation
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of fibroblasts upon deletion of CN is dependent on NFAT-mediated transcription. Initial
studies comparing CsA and FK506/tacrolimus treatment in WT fibroblast-derived matrices
demonstrated that CsA treatment of WT fibroblasts leads to thinner matrices than vehicle
treatment; conversely, FK506 treatment leads to an increase in matrix content and
alignment very similar to that seen in Cn-/- fibroblasts (data not shown). Consistent with
previous literature showing that CsA has anti-fibrotic effects independent of calcineurin
inhibition117, this suggests that the differences in Cn-/- FDMs observed are in fact due to a
reduction in calcineurin activity as opposed to Cre or adenoviral treatment. However,
preliminary data suggests that FK506 increases fibroblast proliferation, which we did not
observe in CN-null fibroblasts. As with any drug, FK506 likely has off-target effects
independent of calcineurin inhibition that may also be affecting these assays. Future
experiments would assess the effects of FK506 or the NFAT inhibitor VIVIT on functional
assays in order to determine whether the CN-null phenotype requires calcineurin
phosphatase activity and/or NFAT-mediated transcription.
One of the most important next steps in the study of calcineurin and fibroblast
homeostasis is to determine the exact transcriptional changes that mediate the functional
differences we have observed upon deletion of CN. First, the NFAT isoforms primarily
responsible for fibroblast activation must be identified. Initial immunofluorescence for
NFAT isoforms has been performed but requires optimization. In this experiment,
fibroblasts treated with various activating stimuli would be probed for nuclear localization
of all four NFAT isoforms in order to determine which translocate to the nucleus upon
activation. Once the predominant NFAT isoforms have been identified, loss- and gain-offunction experiments using deletion or overexpression of specific isoforms could be
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performed to determine whether this phenocopies the results seen in Cn-/- fibroblasts.
Additionally, ChIP for activation-associated genes would determine whether NFAT
occupancy of these genes is altered upon fibroblast activation; ChIP-seq analysis would
identify global changes in NFAT occupancy in the presence of an activating stimulus such
as TGF-b or an increase in substratum stiffness.
While my work has identified how CN deletion affects several functions of
activated fibroblasts, it is still unclear how CN regulates their transdifferentiation into
specific subtypes of activated fibroblasts. One aspect of fibroblast activation that is
incompletely studied in my work is the heterogeneous nature of activated fibroblasts, and
indeed, fibroblasts in general. Beyond FAP and aSMA, a large number of other activated
fibroblast markers define a large number of subsets of activated fibroblasts. While these
markers often overlap, completely profiling the activation markers expressed by Cn-/fibroblasts at baseline and in the presence of activating stimuli such as TGF-b or
mechanical stiffness would help to define how exactly calcineurin modulates fibroblast
activation, and in which populations. Better knowledge of how CN informs fibroblast
heterogeneity will identify which specific subsets of activated fibroblasts are targeted by
calcineurin inhibitor therapy, thus better defining the specific effects on the stroma as well
as the tumor microenvironment in general.
Future experiments should also characterize the role of CN in fibroblast-mediated
remodeling of the ECM and subsequent cytoskeletal reorganization of fibroblasts cultured
on WT vs Cn-/- FDMs. The effects of CN deletion on expression and activity of MMPs as
well as lysyl oxidase (LOX) and other collagen cross-linking enzymes should be
investigated, as these remodeling enzymes are known to contribute to the linearization of
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collagen fibers during matrix remodeling. While my studies have focused on the role of
CN in fibroblast-mediated collagen deposition and remodeling, the effects of CN deletion
on other ECM proteins should be studied as well. As mentioned in Chapter 1, the ECM
consists of significant amounts of fibronectin and hyaluronic acid, among other proteins,
whose secretion and structure can be altered by activated fibroblasts. Expression analysis
of a wide variety of ECM proteins and matrix remodeling enzymes at both the mRNA and
protein levels would determine whether the increase in fibrillar collagen signal induced by
Cn-/- fibroblasts in type I collagen gels and FDMs is due to increased ECM expression,
increased matrix remodeling, or both.
The immediate next steps to identify the specific role that calcineurin plays in TGFb-mediated activation are, as previously discussed in Chapter 3, to examine the canonical
and noncanonical TGF-b signaling pathways downstream of receptor binding and Smad
phosphorylation to better examine where the specific block in signaling is located. Further
studies with a large variety of activating stimuli should be performed to specifically
identify the role of CN in each of these settings. This will determine whether CN signaling
is required for the response to specific stimuli or more generally restrains fibroblast
activation in response to all activating stimuli.
While we have shown that deletion of calcineurin leads to a phenotype consistent
with fibroblast activation, it is also important to determine whether the converse is true, i.e.
if increased activation of the calcineurin/NFAT pathway induces a quiescent fibroblast
phenotype. This will identify whether calcineurin maintains homeostasis, suppresses
activation, or both. This can be accomplished either by expressing a constitutively active
mutant of CN or NFAT, or by deleting an endogenous calcineurin inhibitor such as Dscr1.
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However, our work using the Dscr1-null mouse demonstrates that the response to
calcineurin signaling often follows a bell-shaped curve; either too little or too much
calcineurin signaling can have similar effects105. It may be that excessive activation of
calcineurin signaling also has an activating effect in lung fibroblasts, as was observed by
Davis et al164.

Stromal CN deletion restrains metastatic outgrowth
The studies examining stromal CN deletion in mice I have performed show that
stromal CN in the lung serves to restrain lung metastasis growth; deletion of CN from lung
fibroblasts encourages outgrowth of lung metastases, leading to larger tumor sizes. This
could be through a variety of mechanisms. First, Finally, the alterations in secretion and
remodeling of extracellular matrix could create a pro-tumorigenic collagen signature in
both the lung and the metastases; as the FDMs represented a shift from TACS 1-2 to TACS
2-3 upon calcineurin deletion, the effects on matrix in vivo could similarly remove
collagen-induced restraints on tumor growth. However, picrosirius red staining reveals that
fibrillar collagen content in PDAC lung metastases is minimal, and there is not a noticeable
capsule around these tumors. Therefore, the effects of stromal CN deletion could also
include other components of the ECM that also affect tumor outgrowth, such as fibronectin.
In addition, my work broadens the understanding of the expression pattern 2.3kb
fragment of the Col1a1 promoter. Previous work had suggested that this fragment of the
promoter was specific only to osteoblasts and osteoclasts and expressed at lower levels in
dermal fibroblasts. However, the previous studies only examined expression in lung
fibroblasts of embryonic mice whose mothers had been given tamoxifen, and expression
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in adult lung fibroblasts had not yet been assessed. I have shown that the 2.3kb-Col1a1Cre-ER(T) is expressed in lung fibroblasts by qPCR and by demonstrating CN deletion in
isolated lung fibroblasts. This underlines the importance of examining tissue-specific
promoter expression in adult as well as embryonic mice.
As was discussed previously, one of the difficulties inherent in studying the effects
of tissue-specific gene deletion in vivo is that the correct disease model, time points, and
variables must be chosen in order for the results to be physiologically relevant, or in our
case, even detected in the first place. It is important to consider that in vivo models featuring
activated fibroblasts may not in fact be the best method of studying stromal CN deletion.
Given that our major in vitro phenotypes exist in the absence of activating stimuli, it may
be that stromal CN deletion has long-term effects on normal tissues due to the constant
activation of fibroblasts.

Future directions to characterize the effects of stromal CN deletion in vivo
There remains a significant amount of phenotypic profiling of the stromal CN-null
mouse that needs to be performed. First, given that calcineurin deletion in vitro led to
significant phenotypic differences in baseline states as opposed to activated states, the
lungs and skin of these mice should be analyzed for baseline collagen content and
architecture, as well as fibroblast activation marker expression. In addition, aging-related
organ fibrosis (e.g. renal, dermal, pulmonary, and cardiac fibrosis) should be compared
between WT and stromal CN-null mice; while aging is a process that involves
inflammation and fibroblast activation, increased amounts of baseline stromal activation
may shift the kinetics and/or increase the severity of aging-related fibrosis. By lowering
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the “activation threshold” of fibroblasts, aging-related changes such as fibrosis and
senescence may be more dramatic in the setting of stromal CN deletion.
As previously discussed, future experiments should also continue and expand on
the investigation of the role of stromal CN deletion in various disease models. Bleomycin
lung fibrosis and dermal wound healing assays could be modified in a way that maximizes
the differences between WT and stromal CN-null mice. There are also many aspects of
both primary tumors and lung metastases that could be investigated, such as the effects of
CN

deletion

on

immune

surveillance,

tumor

angiogenesis,

and

collagen

architecture/remodeling over the course of tumor growth and progression. The tumors that
were resected in our models of metastasis were sufficiently large to have already surpassed
the angiogenic and stromagenic switches, and analyzing large tumors may not detect
differences in a model in which activation and homeostasis are affected in baseline
conditions. This may explain why preliminary studies examining the vasculature in these
resected tumors did not demonstrate large differences in vessel density. Our data suggest
that stromal deletion of CN may alter very early stages of micrometastatic outgrowth in a
lung colonization model of tumor growth. Thus, analysis of primary tumors and metastases
should be performed at multiple time points starting at very early stages to determine the
effects of stromal CN deletion on the kinetics of stromal activation in tumorigenesis and
metastasis. It may be that lowering the activation threshold by deleting calcineurin leads to
earlier triggering of the angiogenic and/or stromagenic switch.
Finally, to complement the current model, deletion of CN from the stroma could
be performed using a variety of other methods. First, I have obtained a mouse expressing
Cre-ER(T) driven by the Col1a2 promoter, a promoter that is known for being more
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broadly expressed across all fibroblasts and connective tissue in the body, and am in the
process of crossing this mouse to CnBfl/fl mice in order to potentially achieve higher
proportions of CN deletion in lung fibroblasts, as well as to compare the effects of CN
deletion in fibroblasts expressing the Col1a1 vs Col1a2 promoter. Additionally, use of
other fibroblast or activated fibroblast promoters in the deletion of CN would complement
the in vitro phenotypic profiling experiments mentioned above; by deleting calcineurin
specifically from aSMA, FAP, or PDGFR-expressing fibroblasts, for example, we would
be able to better understand the ways in which CN expression is required for the
homeostasis or activation of those specific fibroblast sub-populations.

Clinical implications
This work identifies another possible mechanism through which chronic
calcineurin inhibition may lead to increased malignancy in transplant patients. Previously,
the pathophysiology of calcineurin inhibitor-induced malignancy had been mainly
suggested to be via its immune suppressive properties101. However, our data suggest that
another mechanism through which these drugs may lead to an increase in tumor formation
is through their effects on the stroma. Some of the pro-tumorigenic effects of calcineurin
inhibition on the stroma may in fact have effects on the immune system through decreased
immune surveillance of tumors or increase in overall inflammation. However, we showed
that calcineurin deletion leads to pro-tumorigenic changes in collagen deposition,
remodeling, and contractility, thus it is very likely that chronic calcineurin inhibitor
treatment also leads to the formation of pro-tumorigenic ECM in tissues, thus facilitating
the formation of malignancies. By understanding the mechanism through which chronic
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calcineurin inhibition might create a tumor-permissive stroma, we can potentially develop
drugs that prevent this baseline stromal activation and at least partially mitigate the increase
in malignancy and fibrotic disease observed in transplant patients.
It is important to note that our work furthers the biological understanding of CNmediated fibroblast homeostasis, but there is still a significant amount of work that remains
in order for this to translate to specific therapies in the future. Given that calcineurin plays
such important and vastly differing roles in different tissues, any modality that broadly
targets calcineurin/NFAT will likely have significant on- and off-target effects that will
complicate or likely render these therapies ineffective. Because of this, further work needs
to be performed in order to determine more specific downstream targets of CN/NFAT
signaling as previously described. Given its role as a homeostatic regulator, there are two
potential methods of targeting CN/NFAT signaling in a way that abrogates fibroblast
activation. First, certain pro-activation genes can be negatively targeted to block stromal
activation, a modality that is currently being studied to varying degrees of success as
discussed in Chapter 1. Second, and more novel, specific homeostatic regulators could be
positively targeted to increase their function and maintain fibroblast homeostasis in the
face of activating stimuli such as cancer or inflammation. Before clinical therapies can be
developed, further work needs to be done to identify the specific molecular mechanisms
through which calcineurin maintains the quiescent fibroblast phenotype.
There are several potential clinical-translational applications of this data. Increased
understanding of the ways in which CN regulates specific fibroblast activation-associated
genes could be used to better target the activation of stromal cells in both the primary tumor
and distant metastatic sites. However, just as targeting angiogenesis alone resulted in
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limited efficacy, so too will stroma-targeting therapies likely need to be used in
adjunctively with other methods of treatment. Ideally, inducing homeostasis or blocking
activation through CN-mediated processes would increase the efficacy of other cancer
therapies, such as traditional chemotherapy or immunotherapy. That having been said, as
early cancer screening and detection continues to improve, we may be able to use these
modalities to target the stroma at the distant site in a way that prevents the colonization
and/or outgrowth of metastases, so that patients with early-stage cancer may receive these
treatments in order to ensure that their disease does not progress.
In conclusion, my work has identified CN as a novel regulator of fibroblast
homeostasis. While further studies will be required in order to translate these findings into
clinical therapies, these data raise interesting questions regarding the maintenance of the
quiescent and activated states in fibroblasts, and they provide potential alternate
mechanisms for the increase in tumorigenesis observed in transplant patients receiving
long-term calcineurin inhibition therapy.
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MATERIALS AND METHODS

Primary lung fibroblast isolation and culture
Fibroblasts were cultured in DMEM-F12 + L-glutamine (Gibco) with 10% heatinactivated FBS, L-glutamine, and penicillin-streptomycin. To isolate primary lung
fibroblasts, lungs from male and female 3-5-week-old mice were dissociated in Hank’s
buffered saline solution (HBSS) containing 5 mg/ml type II collagenase and 0.5 mg/ml
deoxyribonuclease I (Worthington, #LS004176 and #LS002139) in the Miltenyi
GentleMACS Octo. Dissociated lungs were passed through 100µm and 40µm filters to
obtain a single cell suspension before resuspending in culture media and plating; fibroblasts
were allowed to adhere for 1-2 hours at 37o C before non-adherent cells were washed off.
Fibroblast identity was confirmed by immunostaining cultured cells for vimentin (goat,
Santa Cruz #sc-7557, 1:100), CD45.2 (biotinylated mouse, BD Pharmingen #553771,
1:100), and CD31 (rat, BD Pharmingen #553370, 1:100), followed by secondary antibody
and streptavidin (Alexa Fluor 647 anti-goat IgG, Alexa Fluor 488 anti-rat IgG, Alexa Fluor
555 streptavidin, all 1:100: Invitrogen #A-21447, A-11006, Thermo Fisher #S-21381
respectively); fibroblasts were >99% vimentin-positive, with <5% CD45+ contaminants
and no CD31+ cells present.
For soft collagen gel cultures, fibroblasts were plated on thick 1 mg/ml type I
collagen gels; type I rat tail collagen (Corning #354236) was diluted in 10X PBS and sterile
ddH2O at 1 mg/ml and neutralized using 1 N NaOH per manufacturer’s instructions.
Collagen gels were allowed to solidify for 1-3 hours prior to plating. Fibroblasts were
plated onto collagen gels and cultured for 48 hours prior to phase contrast and multiphoton
second harmonic generation (2P-SHG) imaging.
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Acute deletion of calcineurin in vitro
To acutely delete calcineurin B (CnB) in vitro, P1 CnBfl/fl fibroblasts were treated
with 300 MOI AdCMV-Cre (U Iowa Viral Vector Core Facility) overnight in 10% serum
media; culture media was washed out and cells were washed with PBS before replacing
with fresh culture media and allowing the cells to recover for a day. Fibroblasts were
passaged once prior to use in experiments; all fibroblasts were passage 3 at the time of use
in experiments. Controls were either WT fibroblasts treated with AdCre, CnBfl/fl fibroblasts
from the same isolation treated with AdGFP, or CnBfl/fl fibroblasts from the same isolation
without viral transduction. CnB deletion was confirmed by Western blot for calcineurin A
as described below.

Proliferation assays
For proliferation assays, fibroblasts were plated in gelatin-coated 24-well plates and
serum-starved overnight. Day 0 counts were measured, then media was exchanged for
either 1% or 10% FBS + DMEM-F12 culture media. On each measurement day, 3 wells
per condition were trypsinized, and dead cells were stained with trypan blue before
counting using a hemocytometer. EdU proliferation assays were performed on gelatincoated chamber slides using the Click-iT EdU Alexa Fluor 594 Imaging Kit (Invitrogen)
according to manufacturer’s instructions; fibroblasts were pulsed with 10 µM EdU for 1618 hours prior to fixation and staining.

In vitro scratch wound healing assays and live-cell imaging
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Scratch assays were performed as described previously156. Briefly, cells were plated
at 100% confluence in 12 well plates and allowed to adhere overnight. Cell layers were
wounded using a P200 pipet tip, washed once with PBS, and replaced with DMEM-F12
1% FBS culture media. 2 experimental replicates were imaged at 0, 2, 6, 12, 24, and 48
hours post-wounding using an inverted microscope, and 2 replicates were imaged every 15
minutes using a Nikon inverted microscope with a stage incubator for live cell imaging.
Live cell imaging replicates were stained using the SiR-Hoechst far-red kit (Spirochrome
#CY-SC007), and cell tracking was analyzed using Nikon NIS-Elements software. Each
experimental condition was performed in triplicate.

Transwell migration and invasion assays
For migration and invasion assays, 6.5mm (24 well) and 12mm (12 well) Transwell
inserts with a pore size of 8 µm (Corning) were used respectively. 5 x 104 (6.5mm) or 7.5
x 104 (12mm) WT or Cn-/- fibroblasts were plated into each transwell insert containing
serum-free DMEM-F12 media in the upper chamber and 10% serum containing media in
the lower chamber. For migration assays, inserts were uncoated; for invasion assays, inserts
were coated with 75µl 1mg/ml neutralized type I rat tail collagen and allowed to gel for 1
hour prior to cell seeding. For invasion assays, uncoated transwells were used as a positive
control; for both migration and invasion assays, serum-free media was placed in the lower
chamber as a negative control. 24 hours following plating, the upper chamber was wiped
with a cotton swab to remove any unmigrated cells and washed with PBS; inserts were
fixed and stained in fresh wells containing 0.5% crystal violet in 25% methanol solution
for 15 minutes, washed by dipping in deionized water and allowed to dry completely before
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imaging. Images were taken by inverting the insert onto a glass slide and tile-scanning
using a Zeiss Axio Imager M2 upright microscope with Zen Pro software. The percentage
of crystal violet-positive area on each insert was measured using ImageJ. Each assay was
performed in triplicate, and experiments were repeated at least three times.

2P-SHG imaging and analysis
Images of fibroblasts cultured on collagen and FDMs were acquired using the Leica
SP8 multiphoton upright confocal microscope available through the Penn Vet Imaging
Core. Forward SHG signal was collected, and in non-cell-extracted cultures,
autofluorescence in an adjacent channel was collected to identify cells and differentiate
between SHG and non-SHG signal. 3-5 images per sample were taken for analysis, and Zstacks were performed to obtain maximum intensity projections through the thickness of
the sample. Images were processed using LAS AF software. Where appropriate, collagen
fiber analysis was performed using CT-FIRE and CurveAlign software; fiber alignment
scores were generated in CurveAlign.

Collagen contraction/remodeling assays
Collagen gel contraction assays were performed as previously described127. Briefly,
5 x 105 fibroblasts were embedded in 500 µl of 1 mg/ml rat tail type I collagen solution
(Corning) in a 24 well plate. Collagen gels were allowed to solidify for 1 hour before the
gels were detached and 500 µl of DMEM-F12 1% FBS culture media was added. Images
were taken at 0, 6, 12, 24, 48, and 72 hours post-detachment using a gel documentation
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system. Collagen gel areas were measured using ImageJ software; each time point was
normalized to the area of an empty well. Assays were performed in triplicate.

Measurement of collagenase activity using Type I DQTM Collagen
To visualize collagenase activity, fibroblasts were cultured in chamber slides that
were either coated with gelatin or a thick type I collagen gel as described previously (200
µl/well). DQTM type I collagen from bovine skin conjugated to fluorescein (Invitrogen,
#D12060) or DQTM gelatin from pig skin (Invitrogen, #D12054) was overlaid on cultures
by adding to fresh culture media at 25 µg/ml. After 24 hours of incubation, cultures were
fixed using Prefer glyoxal fixative (Anatech Ltd) or 4% paraformaldehyde (PFA) in PBS
(Affymetrix/USB) and mounted/coverslipped using Fluorogel II with DAPI. Images were
acquired using a Zeiss Axio Imager M2 upright fluorescent microscope and processed with
Zen Pro software.

Fibroblast-derived matrix (FDM) generation, extraction, and analysis
FDMs were generated as per Cukierman et al.128. Briefly, 5 x 105 (35mm dish), 2 x
105 (12 well plate), or 5 x 104 (35mm glass bottom dish) fibroblasts were plated onto
gelatin-crosslinked dishes to 100% confluency. 75 µg/ml L-ascorbic acid (Sigma-Aldrich
#A4544) was added to complete culture media and changed every other day for 8-10 days
(35mm dish). Matrices were decellularized using 0.5% Triton X-100 and 20 mM NH4OH
in PBS and stabilized at 4o C overnight before use. For analysis of earlier time points,
FDMs were generated in triplicate in 12 well plates, and matrices were decellularized,
extracted and solubilized following 3 and 5 days of ascorbic acid treatment.
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To generate tumor cell-conditioned media, SR0144 lung tumor cells (generously
provided by Dr. Carla Kim, Harvard University) were grown to 80% confluence, and
culture media was replaced with serum-free DMEM for 24 hours. Conditioned media was
centrifugated to remove all cells and insoluble material prior to use. Media for unstimulated
and tumor-conditioned FDMs had a final serum concentration of 2.5% and consisted of a
1:1 dilution of either tumor-conditioned media or serum-free DMEM with 5% FBS
DMEM-F12, with a total concentration of 75 µg/ml L-ascorbic acid as above.

Western blotting of cell lysates and FDMs
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA, 50 mmol/L TrisHCl pH 8, 150 mmol/L NaCl, 1% Triton-X, 0.5% sodium deoxycholate, and 0.1% SDS),
centrifuged at 16,000 x g for 10 minutes, and supernatant was collected. Total protein
content was quantified using BCA assay (Pierce). FDMs were solubilized in Protein
Extraction Reagent Type 4 (Sigma-Aldrich C0356) and stored at -80 C until use. Protein
loading of FDMs was normalized using the Bio-Rad Protein Assay Kit on samples diluted
1:10. Total protein of FDMs was analyzed by running samples in 4x Laemmli sample
buffer (Bio-Rad) on a 4-12% gradient gel (Invitrogen) and silver staining using a kit
(Pierce). SDS-PAGE of lysates was performed using 3-10 µg per sample at 120-150 V on
8, 10, or 12% gels depending on the size of the protein in question using the Bio-Rad Mini
Protean Tetra Cell system. Proteins were transferred onto nitrocellulose or PVDF
membranes at 90 V for 2 hours using the Bio-Rad Mini Trans-Blot system. Blots were
blocked in 5% non-fat dry milk (LabScientific M-0841) in TBS-T (TBS + 0.1% Tween 20)
and incubated with primary antibody diluted in blocking buffer at 4o C overnight
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(calcineurin A: 1:2000, Abcam #ab3673; actin: 1:5000, Sigma #A2668). Blots were
washed in TBS-T, and secondary antibody (anti-rabbit IgG HRP conjugate, Cell Signaling
CST7074, 1:1000-1:5000) was incubated in blocking buffer for 1 h at room temperature
then washed with TBS-T. Bands were visualized using enhanced chemiluminescence
reagent (100 mM Tris pH 8.6, 0.2 mM p-coumaric acid, 1.25 mM luminol, 2.6 mM).

Imaging analysis of cell behavior on FDMs
104 WT or Cn-/- fibroblasts or MH6449 PDAC cells were plated in 35mm wells
containing either WT or Cn-/- FDMs and allowed to adhere for 16 h before fixing with 4%
PFA in PBS. Wells were blocked with 5% normal goat serum, 1% BSA, and 0.001%
thimerosal in PBS, followed by Fc receptor blocking for 20 minutes (1:200, BD
Pharmingen #553141). Primary antibodies were incubated in blocking buffer at 4o C
overnight (paxillin: 1:100, BD Biosciences #612405), and secondary antibodies were
incubated in 1% BSA in PBS for 1 h at RT. Following secondary antibody incubation
(1:1000, Invitrogen #A-11032) cells were incubated with Alexa Fluor 488-conjugated
phalloidin (1:40, Cell Signaling Technologies, #8878S) prior to mounting and
coverslipping with Fluorogel II with DAPI. Confocal imaging was performed on a Leica
TCS SP5 laser scanning confocal microscope and processed using LAS AF software.
For live cell imaging studies, WT and Cn-/- FDMs were generated and
decellularized in 12 well plates. 5 x 104 YFP+ MH6449 PDAC cells or 1 x 105 GFP+
primary lung ECs were plated onto decellularized matrices, and cell movement was tracked
for 24 hours following plating using a Nikon inverted microscope with stage incubator for
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live cell imaging. Individual cell tracking and velocity/direction analysis was performed
using Nikon NIS-Elements software.

Endothelial cell co-culture assays and angiogenic secretome analysis
Primary GFP+ lung endothelial cells (ECs) were isolated as described previously165
using CD31 MicroBeads (Miltenyi Biotec #130-097-148) and cultured in Advanced
DMEM (Gibco) + 15% FBS, 25 mM HEPES, 0.1 mg/ml heparin, 100 µg/ml bovine
endothelial

growth

supplement

(Alfa

Aesar

#J64516),

L-glutamine,

and

penicillin/streptomycin. On day 0 of the experiment, 2.5x105 each of fibroblasts and ECs
were mixed 1:1 and embedded in growth factor reduced basement membrane extract
(BME, Trevigen #3533-001-02) in 35mm glass bottom dishes. After 1 hour, organoid
media (DMEM-F12, 10% KnockOut Serum Replacement (Gibco), 1x Insulin-TransferrinSelenium (Gibco), L-glutamine, penicillin/streptomycin) was added, and 3-5 phasecontrast and fluorescence images per sample were taken at 0, 12, 24, 48, and 72 hours using
an inverted tissue culture microscope with GFP filter. Tube formation was quantified by
counting the number of tubes per high power field. Conditioned media for angiogenic
secretome analysis was generated by culturing fibroblasts on BME in serum-free media for
24 hours prior to collection. Conditioned media was analyzed using the Proteome Profiler
Mouse Angiogenesis Array (R&D #ARY015). Conditioned media (750 µl/sample) was
hybridized to membranes, and chemiluminescent signal was normalized to total protein
content using lysate from fibroblast cultures.

In vivo model of stromal-specific calcineurin deletion
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The University of Pennsylvania Animal Care and Use Committee approved all
studies. Mice with inducible stromal-specific deletion of calcineurin B were obtained by
cross-breeding C57Bl/6 Cnb1fl/fl mice126 with C57Bl/6 Col1a1-Cre-ER(T) mice (JAX
#016241) 133. Breeding cages were maintained using Cola1-Cre;CnBfl/fl crossed to CnBfl/fl
in order to ensure hemizygosity of the Cre transgene. In order to acutely delete CnB in vivo,
mice were given 1 mg tamoxifen in 100 µl corn or peanut oil (Sigma-Aldrich)
intraperitoneally daily for 5 days, followed by 2 days without treatment. During tumor
experiments, mice received 1-2 additional doses of tamoxifen per week to account for
recruitment of bone marrow-derived stromal cells. Calcineurin deletion was confirmed by
Western blot of isolated lung fibroblasts; lungs were dissociated and plated as described
above, and after 30-60 minutes, non-adherent cells were removed and the adherent cell
layer washed with PBS and collected in lysis buffer.
To confirm Col1a1-Cre-ER(T) mRNA expression in lung fibroblasts, a portion of
isolated lung fibroblasts were taken in Trizol, RNA extracted using the Dymo Direct-ZOL
kit with on-column DNase digestion, and reverse transcription performed using the
Applied Biosciences High Capacity cDNA Reverse Transcription Kit. A total of 200ng of
cDNAs per qPCR reaction were added to 2x SYBR Green qPCR Master Mix (Bimake),
and reactions were run and measured using the ViiA 7 Real-Time PCR System. Primers:
GAPDH:

forward

5’-AGGTCGGTGTGAACGGATTTG-3’

TGTAGACCATGTAGTTGAGGTCA-3’

and

Col1a1-Cre:

and

reverse
forward

5’5’-

CCAGCCGCAAAGAGTCTACA-3’ and reverse 5’-ACAATCAAGGGTCCCCAAAC3’.
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Injection-resection model of lung metastasis
Lewis lung carcinoma (LLC) cells were obtained from ATCC; MH6449 KPY
PDAC cells were a generous gift from Dr. Ben Stanger at the University of Pennsylvania.
Tumor cells were cultured in DMEM + 4 g/L glucose (Gibco), 10% heat-inactivated FBS
(Gemini), L-glutamine (Gibco), and penicillin-streptomycin (Lonza). Tumor cells were
passaged to be 70-80% confluent on the day of injection. Mice were 8-12 weeks at the time
of tumor injection with the exception of one PDAC injection-resection experiment, in
which mice were approximately 52 weeks of age and had been receiving tamoxifen weekly.
Tumors were established by injecting 1x106 (PDAC) or 5x106 (LLC) tumor cells in 100 µl
serum free DMEM subcutaneously into the right hind flank under isoflurane anesthesia.
Tumors were measured using digital calipers, and volume was estimated using the ellipsoid
volume equation V = ½ * width2 * length. Once tumors reached a volume of 400-600 mm3,
they were resected under sterile conditions, and surgical sites were closed using
nonabsorbable monofilament suture (Covidien). Tumors were flash-frozen in OCT
immediately following resection. Mice received 5mg/kg Metacam (Boehringer Ingelheim)
for 3 days following resection, and any dehisced surgical sites were re-sutured if necessary.
14 days after resection, mice were euthanized and lungs were perfused with saline prior to
dissection; lungs were dissected and either formalin-fixed for paraffin embedding or fixed
in 4% PFA followed by incubation in 30% sucrose before freezing in OCT. FFPE samples
were sectioned at 5 µM, and frozen samples were sectioned at 9-10 µM. Lung tumors were
measured and normalized to total lung area using ImageJ software.

Statistical analysis
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Statistical analysis was performed using GraphPad Prism 7. P values were
calculated using Student’s t-test (two-tailed, unpaired) or ANOVA where appropriate.

Materials and Methods: Chapter 3
TGF-b treatment of fibroblasts
Fibroblasts were treated with 0.5-10 ng/ml of pre-activated human TGF-b1 (R&D
Systems). For the majority of activation studies, TGF-b was used at 2ng/ml. Because fetal
bovine serum itself contains TGF-b, unless otherwise specified, studies were conducted in
1% serum containing media to minimize the activating effects of the culture media in
unstimulated conditions.
Cytokine secretome array
Fibroblast-conditioned media was collected from fibroblasts cultured on soft
1mg/ml type I collagen gels by replacing media with serum free culture media +/- 2 ng/ml
TGF-b1 and collecting 24 hours later. Media was centrifuged to remove cells and
particulate matter, and aliquots were flash-frozen and stored at -80 C until use. Secretome
array analysis was performed using 750 µl of conditioned media according to kit
instructions (R&D Systems).
Analysis of TGF-b secretion/activation in scratch assays
In order to assess total TGF-b secretion and latent TGF-b activation, confluent
fibroblast monolayers were either left unwounded or scratched in a cross-hatch pattern with
a sterile plastic comb before being washed with PBS, and media was replaced with serum
free culture media containing 30 ng/ml latent TGF-b1 (R&D Systems). Media was
collected 24 hours later, centrifuged to remove cells and debris, flash-frozen on dry ice,
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and stored at -80 C until use. Cell layers were lysed in RIPA buffer, and lysate protein
concentration was determined by BCA for sample normalization. A sandwich ELISA kit
for TGF-b1 (Enzo Biosciences) was used to determine both activated and total TGF content
in conditioned media. For activated TGF, samples were used undiluted; for total TGF,
samples were pre-activated with 1 N HCl according to kit instructions and diluted 1:10 in
sample dilution buffer prior to use.
Western blot of Smad2 phosphorylation
Western blots were performed as previously described. pSmad2: 1:1000, Cell
Signaling; tSmad2/3: 1:1000, Cell Signaling. pSmad signal was assessed first, then blots
were stripped by washing 3 x 15min in TBS-T before re-blocking in 5% milk and
incubating with tSmad2/3 antibody. pSmad signal was visualized using Femto ECL reagent
(Thermo Fisher); tSmad signal was visualized using previously described homemade ECL
reagent.

Materials and Methods: Chapter 4
Polyacrylamide hydrogel assays and flow cytometry
Polyacrylamide hydrogels were generated according to the protocols created by Dr.
Richard Assoian’s group.160 They were either acquired from the University of
Pennsylvania ITMAT Core Facility or generated by myself according to their protocol.
Hydrogels were coated with fibronectin solution at least overnight prior to use. Prior to
plating, hydrogels were transferred with sterile forceps to tissue culture wells coated with
1% agarose to prevent cell adhesion to the well. 40mm hydrogels were plated with 1.5x105
(20-25 kPa) or 3.5x105 (2 kPa) fibroblasts depending on their stiffness; cells were cultured
95

for 48 hours in full serum media prior to use in downstream assays. For phalloidin imaging,
12mm hydrogels were used, and cell numbers scaled down accordingly. Phalloidin staining
was performed as described previously.
For flow cytometry experiments, cells were collected via trypsinization and
pelleted in a 96 well plate for all staining steps. Fibroblasts plated on plastic were used for
single stain compensation controls and isotype antibody controls. All staining steps were
performed in FACS buffer (2% FBS in PBS). Following 15 minutes of Fc block (1:200),
primary antibody (biotinylated mouse anti-FAP, 1:124; isotype biotinylated mouse IgGK1,
1:100, BD #550615) was incubated for 30 minutes at room temperature, followed by
incubation with APC-conjugated streptavidin for 15 minutes (1:200). Live-dead staining
was performed using the Fixable Violet Dead Cell Stain Kit (Molecular Probes). Cells were
fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) prior to staining
with FITC-aSMA antibody (1:270, Sigma #F3777; isotype FITC-IgG2a, 1:50). Samples
were analyzed on an Attune NxT flow cytometer (Thermo Fisher).
Intravenous tumor cell colonization assays
SKPY42.1 tumor cells were obtained by isolating tumor cells from the sarcoma of
a KPY (KrasG12D;p53fl/fl;Rosa26-LSL-YFP) mouse that had received AdCre injection in
the hindlimb161; tumors were dissociated using the gentleMACS Octo with heating
element, and cell suspensions were plated in 10% FBS DMEM and allowed to adhere
overnight before washing the cell layer. Single cell clones of these tumor cell lines were
obtained by serial dilution, and the subclones with the greatest invasive capability in in
vitro Matrigel-coated Transwell assays were identified. Cells were cultured in 10% FBS
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DMEM + 4 g/L glucose + L-glutamine + pen/strep and passaged to 70-80% confluence
prior to use in experiments.
CnBfl/fl and Col1a1-Cre;CnBfl/fl mice were treated with tamoxifen as described prior
to use in tail vein injection assays. On the day of injection, 3x105 cells in 100 µl serum free
DMEM were injected into the lateral tail vein of each mouse using a restrainer. Starting
the day after tail vein injection, tamoxifen was continuously administered 2-3 times per
week where noted. Mice were euthanized and lungs harvested at the indicated time points.
Lung analysis was performed using H&E stained paraffin sections as described previously,
and images were analyzed using ImageJ software.
Bleomycin model of lung fibrosis
Mice were treated with tamoxifen as described previously prior to the start of the
assay. For bleomycin lung fibrosis assays, a total of 5 doses of bleomycin (1 U per mouse
in 400ul PBS for a dosage of 50 U/kg) were administered intraperitoneally every 5 days;
mice were sacrificed 5 days after the final bleomycin injection. PBS was used as a vehicle
for untreated controls. Lung analysis was performed using Masson’s trichrome stained
paraffin sections, and images were analyzed using ImageJ software.
Assessment of cutaneous wound healing
Mice were treated with tamoxifen as described previously prior to the start of the
assay. Dermal wounds were generated on the dorsum of the mouse using bilateral 6mm
punch biopsies under isoflurane anesthesia. Every other day, mice were briefly placed
under isoflurane anesthesia, and wounds were imaged using a digital camera with a ruler
for reference. Wounds were covered using non-adhesive gauze pads to prevent scabbing
and interference with wound healing. This experiment was repeated a total of three times,
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once without covering the wound and twice covering the wounds. Wound area was
measured using ImageJ.
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